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General introduction and aims of this thesis 
Introduction
The condition of Chronic Heart Failure (CHF) is currently a large public health problem. 
Patients with CHF have a high risk of death and cardiovascular complications and the preva-
lence of CHF is still increasing. The Framingham study demonstrated that the life time risk 
for developing CHF is 1 in 5 for both men and women(1). The etiology of CHF is diverse, 
but coronary artery disease leading to myocardial infarction is the main cause of CHF. Several 
other factors are involved in the etiology of CHF including hypertension, valvular disease, 
myocarditis and cardiomyopathy.  
Pathophysiology of CHF
In CHF, independent of the aetiology, cardiac wall stress is increased and results in increased 
energy and oxygen demand. While myocardial perfusion at rest is often relatively normal, 
blood flow during exercise or after vasodilation is frequently impaired(2-4). The result of 
this apparent imbalance between oxygen demand and supply may play a key role in the 
pathophysiology of CHF. This has been observed, not only in patients with epicardial vascu-
lar disease but also in patients with idiopathic dilated cardiomyopathy (IDC), who have by 
definition anatomically normal coronary arteries(5-7). Van den Heuvel et al. showed that in 
patients with IDC, a decreased coronary blood flow reserve correlated with the severity of 
left ventricular dysfunction(3). Further evidence for the role of hypoxia in patients with IDC 
was provided by De Jong et al, who showed that 69% of the patients with IDC exhibited a de-
creased wall motion score during stress-testing(8). It is well known that ischemia may result 
in LV dysfunction, but these studies support the theory that the reverse may also be true.
Microvasculature and Neovascularization
Another contributory factor to the presence of hypoxia in CHF may be a deficient microvas-
culature, and in particular impaired new vessel formation (neovascularisation). In CHF, the 
vascular network has to support greater demands of the spared, hypertrophied myocardium. 
The relative insufficient vascularization might play a role in the pathophysiology of CHF. It 
follows that stimulation of neovascularisation may represent a useful therapeutic tool in pa-
tients with CHF(9). Hypoxia and ischemia are important for the upregulation of several pro-
angiogenic factors, including Vascular Endothelial Growth Factor (VEGF) and Erythropoietin 
(EPO). Both proangiogenic factors have also been shown to be involved in the angiogenic re-
sponse to myocardial ischemia(10;11). In vitro, stimulation of cultured endothelial cells with 
EPO resulted in proliferation and formation of vascular structures (12). Jaquet et al. compared 
the angiogenic properties of EPO with VEGF on endothelial cells derived from human myo-
cardial tissue. They found that both proteins exhibited equal angiogenic properties indicating 
a possible pro-angiogenic effect (13). This was further studied in a rat model of stroke. EPO 
treatment, initiated 24 hours after occlusion of the middle cerebral artery, enhanced neovas-
cularization and improved neurological function(14). Background on the effects of EPO on 
endothelial cells and neovascularization is further described in chapter 2. 
Besides EPO, also VEGF levels may influence neovascularization in CHF and it is tempting to 
speculate this consequently influences outcome. Several polymorphisms are known in the 
VEGF gene and some are associated with alterations in VEGF production(15). Recently, we General introduction and aims of this thesis 13
investigated the effect of two common VEGF polymorphisms on morbidity and mortality 
in patients with Chronic Heart Failure, in a substudy of the MERIT-HF trial(16). We found 
that the presence of the VEGF polymorphism associated with lower VEGF levels was inde-
pendently associated with an adverse outcome. A second VEGF polymorphism not associated 
with different VEGF levels, was not related to an altered prognosis. This study gives, although 
indirect, a clue that VEGF might be related to outcome in CHF patients. 
Renal Function and Anemia
Reduced kidney function and anemia frequently occur in patients with CHF. Previous stud-
ies of our institution showed that as many as 25 to 50% of the CHF population has an es-
timated Gomerular Filtration Rate (GFRc) below 60 ml/min, indicating an impaired renal 
function. It has been demonstrated that renal function is a predictor of mortality in mild to 
advanced CHF patients(17-19). Hillege et al. studied renal function in advanced CHF patients 
and found patients in the lowest quartile of GFR (<44 ml/min) had a 3 times higher risk 
of mortality than patients in the highest quartile (>76 ml/min)(17). Several other studies 
found similar results regarding the prognostic value of kidney function in patients with an 
impaired left ventricular function(17-19). 
In patients with end-stage renal disease anemia is a well-known risk factor for mortality(20). 
This was also shown to be true for patients with CHF. Several studies indicated that anemia 
is commonly observed in patients with CHF (21-23). One of the first studies published on 
anemia and CHF, showed in 142 patients with CHF, that mean hemoglobin (Hb) concen-
tration decreased from 13.7 g/dl (8.6 mmol/L) in mild CHF to 10.9 g/dl (6.8 mmol/L) 
in severe CHF (24). As observed in patients with end-stage renal disease, anemia was not 
only common in CHF, but also associated with a decreased survival (22;23). One of the first 
studies published on this topic was performed by Horwich and colleagues, who found that 
hemoglobin levels < 12.3 g/dl (<7.7 mmol/L) were associated with worsened symptoms 
and an impaired survival. These findings were extended by the results of Al-Ahmad et al., who 
showed that an impaired renal function and lower hematocrit levels were both independently 
Figure 1. Standardized  Relative Risk (RR) for all cause mortality predicted by level of GFR and hematocrit. Values are 
standardized to reference levels of hematocritof 45 and GFR of 90 ml/min.Chapter 1 14
associated with higher mortality in CHF patients(25). In addition, in this study it appeared 
that both risk factors have a synergistic relationship, suggesting that anemia and reduction of 
kidney function are more than additive risk factors (Figure 1). 
Erythropoietin
Almost hundred years ago two French scientists, Carnot and Deflandre, hypothesized that a 
circulating factor, hematopoietine, was responsible for the increase in red blood cells(26). 
They came to this theory by previous work from Monsieur Viault, who showed in 1890 that 
hemoglobin was higher in people living at high altitudes in the Andes(27). The name hema-
topoietine was replaced in 1948 by the term erythropoietin. After the purification of EPO in 
1977, cloning was achieved and the subsequent production of recombinant erythropoietin 
lead to the first clinical trials in renal anemia(28). Several small trials in CHF showed benefi-
cial effects of erythropoietin treatment in anemic CHF patients. EPO treatment resulted in an 
improved left ventricular ejection fraction, exercise capacity and in addition decreased the 
need for diuretics and hospital admissions(29;30). 
Recent research indicates that EPO has pleiotropic effects well beyond the maintenance of 
red blood cells. The presence of the EPO-receptor outside the hematopoietic systems provides 
evidence for an autocrine and paracrine function(31;32). 
Aims of this thesis
The first part of the current thesis studies the prevalence and origin of anemia in patients 
with CHF and the role of endogenous EPO herein. In chapter 3 we study the origin of ane-
mia in CHF patients. It has been shown in previous studies that only a minority of the anemic 
CHF patients suffers from hematinic deficiencies and severe renal failure, suggesting other 
factors to play a role in the development of anemia in CHF. This study demonstrates the effect 
of serum of anemic and non-anemic patients on hematopoietic progenitor cells and links the 
renin-angiotensin system with the occurrence of anemia in CHF. Chapter 4 focuses on the 
predictive value for mortality of hemoglobin levels and plasma erythropoietin levels in CHF 
patients. In addition, it describes the correlation between plasma EPO levels and hemoglobin 
levels in CHF patients and controls.
The second part of the thesis emphasizes on the effects of EPO on cardiac function, beyond 
its classical hematopoietic effect. In Chapter 5 the role of EPO and its receptor in the rat heart 
are studied in an ex-vivo ischemia-reperfusion model. In addition the acute effects of EPO 
on apoptosis are investigated. Chapter 6 and 7 describe the results of chronic EPO treatment 
in rats with heart failure after myocardial infarction. In these chapters focus is put on the 
consequences of EPO on neovascularization. In Chapter 8 several aspects of the acute and 
chronic effects of EPO on cardiac function are reviewed. Chapter 9 summarizes this thesis 
and provides future perspectives on the origin and consequences of anemia in CHF and the 
results of EPO treatment in CHF beyond hematopoiesis.General introduction and aims of this thesis 15
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Abstract
Several studies showed that anemia is commonly observed in patients with Chronic Heart 
Failure (CHF) and is associated with worsened symptoms and survival. When anemia in 
these patients is treated with erythropoietin (EPO), a significant improvement in cardiac 
function and symptoms was observed. Although it was originally believed that EPO specifi-
cally acted on hematopoietical cells, recent evidence demonstrated several non-hematopoi-
etical effects. Ischemia/reperfusion experiments in rat heart and brain showed large infarct 
reduction when treated with EPO. Other effects of EPO are related to its pro-angiogenic ef-
fects on endothelial cells, which could be of potential value in patients with ischemic heart 
disease. These preclinical findings suggest that EPO may have potential effects in cardiovascu-
lar disease beyond correction of hemoglobin levels.
Introduction
In response to ischemia, mammalian cells express a variety of proteins, including hypoxia 
inducible factor 1α (HIF-1α). Expression of HIF- 1α increases exponentially, as cellular O2 
concentration decreases(1). Downstream effects of increasing levels of HIF-1α are upregu-
lation of various proteins of which erythropoietin (EPO) plays a crucial role. EPO acts as a 
major regulator of erythropoiesis, by promoting the survival and proliferation of erythroid 
precursor cells(2). In response to hypoxia the kidney produces EPO, which in turn increases 
the number of red blood cells and thereby increasing the tissue oxygen supply. 
Cloning of the human EPO gene was achieved in 1983. After the first clinical trials with re-
combinant human erythropoietin (rh-EPO), it has been used for more than a decade in the 
treatment of anemia in end stage renal failure(3). Rh-EPO has a direct effect on hematopoi-
esis, reflected by increased hemoglobin (Hb) levels. Decreased Hb levels are also common 
in patients with chronic heart failure (CHF) and although plasma EPO levels are increased 
in patients with CHF, they are still insufficient to counterbalance the decreased Hb levels(4). 
A recent study in anemic CHF patients showed that rh-EPO therapy significantly improved 
cardiac function and quality of life after correction of the Hb (5). 
However, EPO can also exert non-erythropoietic effects. Recent evidence suggests that ad-
ministration rh-EPO plays a protective role in vascular diseases(6-8). Ischemia/reperfusion 
experiments in rat heart and brain showed large infarct reduction when treated with EPO. 
The favorable effects of these EPO-related changes are still mostly unknown, but may be 
protection from apoptosis and its antioxidative properties (9;10). Other benefits of EPO in 
vascular disease and CHF may be related to its pro-angiogenic potentials(11).  In this review, 
we discuss the current use of rh-EPO in cardiovascular diseases and its possible novel ap-
plications.
Renal failure, anemia and cardiac disease 
Anemia is frequently observed in patients with chronic renal disease (CRF). When the defini-
tion of anemia, according to the World Health Organisation, is used (hemoglobin <12 g/dL 
(7.5 mmol/L) for women, <13 g/dl (8.1 mmol/L) for men and postmenopausal women), Erythropoietin in cardiovascular diseases 21
over 80% of patients with a creatinine clearance < 25 ml/min are anemic(12). Renal anemia 
is an important risk factor for the development of cardiovascular disease(13). A study from 
Foley et al. showed that each 1 g/dl decrease in mean Hb in a renal failure population was 
independently associated with the presence of left ventricular dilatation and the develop-
ment of de novo and recurrent cardiac failure(14). In addition, each 1g/dl decrease in mean 
Hb was also independently associated with mortality. Chronic anemia causes a long-lasting 
volume overload, which results in ventricular dilatation(15). Consequently, the length of 
the sarcomeres increases, leading to a better overlap between myofilaments. Furthermore, 
the thickness of the left ventricle increases to counterbalance the increased radius (eccentric 
hypertrophy). Left ventricular hypertrophy is an independent predictor of cardiovascular dis-
ease and significantly reduces life expectancy(16). A study in New Zealand also demonstrated 
that anemia together with hypertension and diabetes is one of the strongest independent 
predictors of left ventricular hypertrophy in patients with CRF(13). 
EPO treatment in the CRF population
Since the first cloning and clinical testing of rh-EPO, fifteen years ago, the use of rh-EPO has 
become widespread in the treatment of (renal) anemia. More than a decade ago Wizemann et 
al. already showed that rh-EPO treatment in dialysis patients with significant coronary artery 
disease reduces exercise-induced myocardial ischemia, assessed by (ECG) treadmill test(17). 
Furthermore, besides the direct effect on myocardial oxygenation, correction of the anemia 
decreases cardiac output and cardiac workload, thus lowering oxygen consumption(18;19). 
Besarab et al studied 1233 hemodialysis patients with clinically evident ischemic heart disease 
or CHF(20). Patients were randomized to a normal hematocrit group (n=618), in which 
patients received doses of rh-EPO to achieve and maintain a hematocrit of 42%, and a low 
hematocrit group (n=615), in which patients received doses of rh-EPO sufficient to maintain 
a hematocrit of 30%. The primary end-point was time to death or a first non-fatal myocardial 
infarction. After 29 months, there were 183 deaths and 19 non-fatal myocardial infarctions 
among the normal-hematocrit group (42%), and 150 deaths and 14 non-fatal myocardials 
were observed among those in the low-hematocrit group (30%). Although patients in the 
normal-hematocrit group showed a trend towards increased mortality, it is important to note 
that higher rh-EPO doses or hematocrit values themselves were not associated with increased 
mortality. In fact, mortality rates decreased with increasing hematocrit values in each group. 
A randomised cross-over study conducted in Australia investigated the effects of normalis-
ing Hb in comparison with sub-optimal Hb levels in haemodialysis patients treated with 
rh-EPO(21). Patients with higher Hb levels showed a significantly reduced Left Ventricular 
End-Diastolic Diameter (LVEDD). In addition, the incidence of LVH was significantly lower in 
patients with high Hb levels, compared to baseline. A Canadian multicenter trial failed to show 
that normalisation of Hb in patients with asymptomatic cardiomyopathy leads to regression of 
concentric LVH or LV dilatation(22). Nevertheless, treatment may have prevented additional LV 
dilatation. To evaluate the possible effect of rh-EPO therapy on the prevention of LVH, Hayashi 
et al studied the effects of rh-EPO in pre-dialysis patients. In patients with partially corrected 
anemia (Ht 30%) they observed a trend towards a reduction of LVH, whereas in patients with 
normalised Ht (Ht 40%) this decrease appeared to be statistically significant(23). 
Taken together, in the later phases of cardiac disease in patients with CRF, when severe LVH Chapter 2 22
or LV dilatation has developed, the effects of correction of anemia seem to be limited. On the 
other hand, these studies indicate that rh-EPO treatment has at least a favourable effect on the 
prevention of LVH, although the numbers of patients in each trial are low. An explanation for 
its limited effects in advanced heart disease could be the long-lasting development of LVH. 
The accompanied structural abnormalities of the heart, such as interstitial fibrosis (24) can 
lead to irreversible changes of ventricular structure and therefore may reduce the effects of 
treatment with rh-EPO.
Anemia and Chronic Heart Failure 
Anemia is also commonly observed in patients with CHF and is related to the severity of 
disease. In 142 patients with CHF, mean Hb concentration decreased from 13.7 g/dl (8.6 
mmol/l) in mild CHF (New York Heart Association [NYHA] class I) to 10.9 g/dl (6.8 
mmol/l) in severe CHF (NYHA IV)(25). Furthermore, it has been shown that anemia has 
a prognostic value(26). Evidence for a relation between anemia and cardiac morbidity and 
mortality was provided by Al-Ahmad et al.(27). They retrospectively examined the Studies Of 
Left Ventricular Dysfunction (SOLVD) database (n=6.635) and found in univariate analysis 
that a reduced kidney function and lower hematocrit were both a risk factor for all-cause 
mortality. After adjusting for traditional cardiovascular risk markers they found that a 1% 
lower hematocrit was associated with a 1.027 higher risk for all-cause mortality. Similar find-
ings were described by McClellan et al(28). They studied 665 randomly selected patients with 
the primary diagnosis CHF and also found in this population that both hematocrit and serum 
creatinine were independently associated with increased risk of death. Further, Horwich et 
al. studied the relation between anemia and mortality in a prospective cohort study in over 
1000 patients with advanced heart failure (NYHA class III or IV) (26). They conclude that 
even mild degrees of anemia, Hb < 12.3 g/dl (7.7 mmol/l), are associated with an impaired 
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Figure 1. One-year mortality in NYHA functional class III and IV patients for the different hemoglobin levels (26).Erythropoietin in cardiovascular diseases 23
survival, and with worsened symptoms and functional status (figure 1). More evidence that 
anemia is associated with in impaired survival was provided by Ezekowitz et al.(29). They 
studied a large community-based cohort of patients (n=12.065) and found that anemia 
is observed in 17% of the patients and an independent prognostic marker for mortality. To 
determine the prevalence of anemia the authors used the International Classification of Dis-
eases. In using this method, they could not provide a cutoff value for when they considered 
patients to be anemic. Therefore, this study may underestimate the prevalence of anemia in 
community-based patients with CHF(30).
Several factors play a role in the pathogenesis of anemia observed in CHF patients. It is known 
that anemia in chronic inflammatory diseases is associated with increased levels of cytokines, 
like Tumor Necrosis Factor (TNF) alpha.  Recent studies showed that these cytokines play an 
important role in heart failure (31-33). It has been observed that patients with CHF express 
elevated levels of TNF-alpha, which in turn partly inhibits the hematopoiesis, a mechanism 
similar to other chronic diseases associated with anemia. Furthermore, malnutrition could 
play a role in the development of anemia in CHF. Horwich et al. showed that CHF patients 
with lower Hb levels were characterised by lower levels of albumin and a lower body mass 
index(26). The use of angiotensin converting enzyme (ACE) inhibitors, widely used in the 
CHF population, may also reduce the effects of EPO on erythropoiesis(34) and may result 
in anemia(35). In addition, many CHF patients use anti-coagulants, and chronic (micro-
scopic) blood loss may well play a role. Furthermore, anemia can originate from reduced red 
blood cell (RBC) volume, but may also result from increased plasma volume (hemodilution). 
Androne et al evaluated these two origins of anemia in patients with CHF and found that 
hemodilution was observed in 46% of the patients with CHF referred for heart transplanta-
tion(36).  In these two cohorts patients with hemodilution tended to have a higher mortality 
rate than anemia associated with a reduced RBC volume (p=0.08). These results indicate that 
treatment should not only be focussed on elevating RBC volume, but also on adjusting the 
dosage of diuretics in many anemic patients with severe CHF. 
On the other hand, anemia can also provoke or worsen CHF. The interaction between anemia 
and CHF is complex, but there is expanding evidence that CHF can possibly exert anemia. 
Silverberg et al. recently proposed the so-called ‘Cardio-Renal Anemia Syndrome’, which pro-
vides a simple explanation for this phenomenon, where CHF can cause CRF and both can 
then cause anemia (34)(figure 2). Once anemia has developed, the increased cardiac work-
load results in LVH and ultimately worsens the cardiac function, which in turn worsens renal 
function, completing the vicious circle.
The role of rh-EPO in CHF
A recent study of Silverberg et al. showed the beneficial effects of rh-EPO therapy in CHF 
patients(5). They conducted a study in mild anemic patients with severe CHF (NYHA ≥III) 
and treated them with rh-EPO and intravenous iron. Thirty-two patients who had a left ven-
tricular ejection fraction (LVEF) ≤ 40% and whose Hb levels were persistently between 10.0 
and 11.5 g/dl (6.3-7.2 mmol/l) were randomized into two groups. The treatment group 
(16 patients) received rh-EPO and intravenous iron to increase the Hb from a mean of 10.3 
g/dl to 12.9 g/dl (6.4 to 8.1 mmol/l). Over a mean of 8.2 +/- 2.6 months, the treated 
group showed an improvement of 42% in NYHA class, while NYHA class in the control Chapter 2 24
group worsened with 11%. Furthermore, left ventricular ejection fraction increased 5.5% 
in the treatment group, compared to a decrease of 5.4% in the control group. The number 
of hospitalisation days decreased by 79% in the treatment group and increased by 57.6% in 
the control group, compared to the same period before entering the study. Despite the small 
sample size (n = 32) and the open label design of this study, these results strongly suggest an 
important role for rh-EPO in the correction of even mild anemia in CHF. Mancini et al. stud-
ied the effects of rh-EPO on exercise capacity in patients with moderate to severe CHF(37). 
Twenty-six anemic patients with a mean Hb 11.0 g/dL (6.9mmol/L) were randomised to 
receive either EPO (15.000 to 30.000 IU per week) or placebo for three months. They found 
that EPO significantly enhanced exercise capacity, assessed by peak oxygen consumption and 
increased exercise duration, in patients with CHF. Even more important, quality of life was 
also significantly improved in the EPO treated group. Recently Silverberg and colleagues con-
ducted a trial to study the effects of EPO treatment in diabetics and non-diabetics with severe 
CHF and mild to moderate renal failure(38). They found that correction of mild anemia (Hb 
9.5-11.5 g/dL, [5.9-7.2 mmol/L]) in diabetics and non-diabetics resulted in an improved 
cardiac function, a better quality of life and a reduction in the number of hospitalisations. 
Although this was not a randomised placebo-controlled study, the results are comparable 
with previous studies and add to the expanding literature that diabetics benefit as much as 
non-diabetics from EPO treatment.  
Anti-apoptotic effects of EPO 
The previously described beneficial effects of rh-EPO on left ventricular structure and func-
tion are mainly explained by its effects on erythropoiesis. However, expanding evidence 
suggests that EPO plays a major role in non-erythropoietic processes. Several reports showed 
its efficacy in brain and retinal diseases, mainly by preventing apoptosis(9;39;40). As apop-
tosis has been implicated as a mechanism that contributes to the loss of cardiomyocytes in 
CHF(40) and ischemic injury(41), rh-EPO may have beneficial effects on these diseases as 
well.
Most of the anti-apoptotic effects of EPO are known from the hematological field. EPO is 
the primary regulator of erythropoiesis, and promotes the proliferation and differentia-
tion of erythroid progenitor cells(2). It does so, at least partially, by preventing immature 
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erythroblasts from apoptotic cell death. EPO binds to a specific transmembrane receptor: the 
EPO-receptor (EPO-R). After binding with EPO, various signalling pathways are simultane-
ously activated, including the MAPK p42/44, JAK2-STAT5 and the PI-3-AKT proteins. Stud-
ies performed on immortalised human cell lines suggest that cell proliferation is regulated 
mainly by activation of MAPK p42/44 or JAK2-STAT5 and inhibition of apoptosis mostly by 
activation of the PI-3K-AKT axis or JAK2-STAT5(42). In the latter case, phosphorylated Jak2 
triggers the activation of STAT5 protein and the activated STAT5 translocates into the nucleus, 
where it binds to specific DNA response elements and induces a cascade of cellular responses, 
including the upregulation of the anti-apoptotic genes such as bcl-2 and bcl-XL (43;44). 
This anti-apoptotic mechanism is not only important in erythropoiesis, but also appears to 
play an important role in other processes with high apoptotic activity, for example in stroke, 
retinal diseases and possibly myocardial infarction and CHF(7;40;41;45).
Effects of EPO on angiogenesis
Beside its anti-apoptotic effects, other non-erythropoietic effects of EPO have been described. 
A study of Juul et al revealed the presence of EPO and EPO-R in human fetal tissue. Although 
the heart showed minor amounts of EPO, the EPO-R was abundantly expressed in the myocar-
dium as gestation progressed, indicating its presence in adult cardiac tissue(46). Recently we 
found that EPO-R is also expressed in the adult heart, including endothelial cells, fibroblasts 
and to a lesser extent on cardiomyocytes(47). Experiments with mice deleted (knocked-out) 
for the gene expressing EPO and EPO-R provided more evidence for its role in cardiac tissue 
as both EPO-/- and EPO-R-/- mice suffer from ventricular hypoplasia(48). This defect appears 
to be independent from the hypoxic state and is likely due to a reduction in the number of 
proliferating cardiac myocytes in the ventricular myocardium. To support this concept, ad-
ditional experiments were performed under cultured conditions. In these experiments, Wu 
et al. found that EPO acts as a mitogen in isolated cardiomyocytes from EPO-/- and wild type 
mice, while it has no effect in EPO-R-/- mice(48). These findings together strongly suggest 
that EPO and its receptor, at least during fetal life, stimulate cardiomyocyte proliferation.  
Another interesting observation in the experiments with EPO knockout mice was that the 
vascular network in the mutant rodent was also severely affected, with a disorganised struc-
ture. Instead of inter-connected, fine vascular networks, the EPO-R-/- heart showed dilated 
and independent vascular clumps(48). Indirect evidence suggests that subtotally nephrect-
omisd rats with moderate renal failure, and presumably low levels of EPO, showed a lack of 
microvessels in the heart(49). The expression of EPO-R has been demonstrated on endothe-
lial cells in vivo and in vitro(50). Stimulation of cultured endothelial cells with rh-EPO resulted 
in cell proliferation and differentiation into vascular structures(11;51) and incubation of 
rat aortic rings with rh-EPO was related to endothelial sprouting(52). Recently, Jaquet et al. 
compared the angiogenic potentials of EPO with VEGF on endothelial cells derived from the 
myocardium(53).  They found that both proteins exhibit equal angiogenic potentials, imply-
ing a role of rh-EPO in vasoproliferative processes. 
Downstream effects of increasing levels of HIF-1α are upregulation of EPO and VEGF, re-
viewed by Jelkmann et al. (54). It is already known that the latter one causes angiogenesis, 
which has also been documented in the myocardium. Recent work of our group showed 
that VEGF might play a role in heart failure, particularly in idiopathic dilated cardiomyopathy Chapter 2 26
(IDC) (55). We observed a decreased capillarisation in IDC, which is disproportionate to the 
rate of hypertrophy and may contribute to the demand-supply mismatch (56). The reason 
for this seemingly decreased angiogenic capacity could be the reduced expression of VEGF in 
IDC. On the other hand, CHF is also associated with an increase in apoptosis (40;57).  Both 
findings in CHF, decreased capillarisation and increased apoptosis could possibly be influ-
enced by rh-EPO due to its anti-apoptotic effects and through stimulation of angiogenesis. 
Recently,  endothelial  progenitor  cells  (EPCs)  have  been  isolated  from  adult  peripheral 
blood(58). It has been shown that they are derived from the bone marrow, and play a role 
in physiological and pathophysiological neovascularisation(58;59).  Heeschen et al. provid-
ed evidence that EPO stimulates neovascularisation, in part by enhancing EPO mobilisation 
from the bone marrow. In addition, they demonstrated, in a model of hind-limb ischemia, 
that EPO increased capillary density by 1.6-fold, compared with control mice. The patho-
physiological relevance of these findings was further elucidated in patients with coronary 
heart disease. They found that patients with unstable coronary heart disease had significantly 
higher serum EPO levels, which were significantly associated with an increased amount of 
functionally active EPCs. Therefore, it is tempting to speculate that the dramatic results of EPO 
treatment in CHF(5) might, in part, be related to the mobilisation of EPCs. 
The role of rh-EPO in stroke
One of the first reports on the effects of EPO and its receptor in brain was published in 1995 
by Digicaylioglu et al(60). They detected functional expression of the EPO-R and a hypoxic 
upregulation of EPO in the brain. Further evidence for this concept was provided by Sakanaka 
et al.(7). In experiments with gerbils, EPO infusion into the lateral brain ventricle was re-
lated to neuronal protection against ischemia-induced cell death. Specificity and biological 
relevance of these changes have been demonstrated by their observation that neutralisation 
of endogenous EPO with soluble EPO-R augments ischemic brain damage. The nature and 
mechanism of the protective role of EPO was further studied by Siren et al (9). They linked the 
prevention of ischemia-induced cell death to the anti-apoptotic effects of EPO. In rats, focal 
ischemia was induced by occlusion of the middle cerebral artery to produce an area of isch-
emia surrounded by a penumbra. In the latter area, programmed cell death is prominently 
present, and the anti-apoptotic effects of systemic rh-EPO therapy are impressive. Adminis-
tration of EPO after 6 hours of arterial occlusion still provided a 50% reduction in infarct 
size, making rh-EPO a potential candidate for the treatment of ischemic diseases in humans. 
The encouraging findings in animal studies resulted in a double blind randomised proof-of-
concept trial to investigate the safety and efficacy of rh-EPO for the treatment of ischemic 
stroke in man(61). Forty patients received either rh-EPO (33.000 U) or saline daily for 
3 days after stroke. No adverse events were observed in the EPO treated groups. After one 
month, they observed an improvement in clinical outcome and a trend towards reduction in 
infarct size, assessed by MRI-scan, in the EPO treated patients (figure 3A). Furthermore, the 
serum marker of brain infarct damage (S100β) was identical in both groups on admission 
and increased after time of infarct, peaking at day 7. The rh-EPO group peaked at a lower level 
than the placebo group (figure 3B). However, larger trials are needed to confirm the trends 
observed in this study. Erythropoietin in cardiovascular diseases 27
The role of rh-EPO in ischemia and myocardial infarction 
As there are many similarities between brain and heart ischemia, recent studies have been 
conducted to evaluate its possible effect in cardiac ischemia. Calvillo et al. assessed the poten-
tial protective role of EPO in vitro with adult rat cardiomyocytes, and in vivo in a rat model 
of myocardial infarction with reperfusion(8). They showed that EPO reduced the amount of 
apoptotic cells by 30% in cell culture and normalised hemodynamic function within one 
week after reperfusion in vivo. Recently we conducted ischemia/reperfusion experiments in 
the isolated rat heart to evaluate possible beneficial effects of EPO treatment (submitted). 
Administration of EPO reduced the cellular damage by 56% (p<0.05) and apoptosis by 15% 
(p<0.05) during reperfusion and resulted in a significantly improved recovery of left ven-
tricular pressure (p=0.02) and coronary flow (p=0.01). Although the mechanism through 
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Figure 3. Evaluation of brain infarct size in patients treated with high dose rh-EPO or placebo for three consecutive 
days (16). Data represent mean +/- SEM. A. Infarct size measured by MRI on baseline and day 18.  B. Time course of 
serum levels of S100β, a marker of brain damage.Chapter 2 28
which EPO preserves cardiac function has yet to be elucidated, it is tempting to speculate 
that anti-apoptotic properties of EPO play a pivotal role. A recent paper from Scarabelli et 
al showed that in the early stages of reperfusion, apoptosis is first seen in endothelial cells 
and then spreads to surrounding cardiomyocytes, suggesting reperfusion induced release of 
pro-apoptotic mediators from endothelial cells(62). Although ischemia is able to initiate the 
apoptotic cascade, reperfusion is required to complete the apoptotic program (63). This is 
consistent with the findings that EPO limits cellular damage mainly during reperfusion, and 
to a lesser extent in the ischemic period. As the EPO-R in the heart is also expressed on endo-
thelial cells, EPO treatment may prevent apoptosis in endothelial cells during reperfusion and 
thereby protect the myocardium and preserving vascular flow. Although these studies were 
all performed in rodents, apoptosis also plays an important role in patients with acute myo-
cardial infarction. Saraste et al. observed apoptotic cardiomyocytes, particularly in the border 
zones of the infarcted myocardium, comparable to the penumbra in brain ischemia(41). As 
the apoptotic activity reaches its peak during the reperfusion period, beneficial effects of rh-
EPO could possibly be achieved in patients receiving trombolytic therapy or after primary 
Percutaneous Coronary Intervention (PCI). Furthermore, it has been shown that EPO influ-
ences, at least during fetal life, cardiomyocyte proliferation. Therefore, it is interesting to 
speculate that infarct size on one hand could be limited through the anti-apoptotic effects of 
rh-EPO, but also could be influenced by increased proliferation. 
Conclusion
Erythropoietin has been used in cardiovascular medicine for many years. Initially, research 
focussed on the direct effect on hematopoiesis and correction of anemia. Normalisation of 
the Hb level in mild anemic patients with CHF showed a positive effect on left ventricular 
function, a reduction in hospitalisation days and even more important an increase in qual-
ity of life. Although it was originally believed that EPO specifically acted on hematopoietical 
cells, recent evidence demonstrated several non-hematopoietical effects. The large reduction 
of infarction size after rh-EPO therapy in ischemia/reperfusion experiments in rat heart and 
brain are promising. As the EPO-R is present in cardiomyocytes and endothelial cells, one 
could speculate about its effects in other cardiac diseases. The anti-apoptotic effects might be 
specifically interesting in patients with CHF and myocardial infarction. The pro-angiogenic 
effects of EPO, as effective as VEGF, are also of potential value in patients with ischemic 
heart disease. Taken together, the future of rh-EPO therapy in cardiovascular diseases seems 
promising. Further basic research into the molecular mechanisms of the apoptosis cascade in 
cardiomyocytes and pro-angiogenic effects on EPCs and endothelial cells will be necessary to 
delineate the benefits of rh-EPO therapy in cardiovascular medicine. Finally, randomised clin-
ical trials have to prove if its theoretical advantages will be translated into clinical practice.  Erythropoietin in cardiovascular diseases 29
References
1.   Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodi   
  mer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
2.   Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992;72:   
  449-89.
3.   Bommer J, Kugel M, Schoeppe W et al. Dose-related effects of recombinant human erythropoietin on    
  erythropoiesis. Results of a multicenter trial in patients with end- stage renal disease. Contrib Nephrol    
  1988;66:85-93.
4.   Volpe M, Tritto C, Testa U et al. Blood levels of erythropoietin in congestive heart failure and correlation  
  with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994;74:468-73.
5.  Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant    
  congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized    
  controlled study. J Am Coll Cardiol 2001;37:1775-80.
6.   Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and    
  cere  bral cortical neurons, and erythropoietin prevents in vitro glutamate- induced neuronal death.    
  Neuroscience 1997;76:105-16.
7.   Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from isch   
  emic damage. Proc Natl Acad Sci U S A 1998;95:4635-40.
8.   Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium    
  from ischemia- reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A    
  2003;100:4802-6.
9.  Siren AL, Fratelli M, Brines M et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia    
  and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044-9.
10.  Chattopadhyay A, Choudhury TD, Bandyopadhyay D, et al. Protective effect of erythropoietin    
  on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol    
  2000;59:419-25.
11.   Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a pro-angiogenic phenotype in cul   
  tured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
12.  Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact   
  of decline in hemoglobin. Am J.Kidney Dis 1999;34:125-34.
13.  Greaves SC, Gamble GD, Collins JF, et al.. Determinants of left ventricular hypertrophy and systolic    
  dysfunction in chronic renal failure. Am J Kidney Dis 1994;24:768-76.
14.   Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and and    
  mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
15.   Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of Edema in Chronic Severe Anemia - Studies    
  of Body-Water and Sodium, Renal-Function, Hemodynamic Variables, and Plasma Hormones. British    
  Heart Journal 1993;70:357-62.Chapter 2 30
16.   Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic  
  uraemia. Nephrol Dial Transplant 1996;11:1277-85.
17.   Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemo 
  dialysis patients with confirmed coronary artery disease. Nephron 1992;62:161-5.
18.   Fellner SK, Lang RM, Neumann A, et al. Cardiovascular Consequences of Correction of the Anemia of  
  Renal-Failure with Erythropoietin. Kidney International 1993;44:1309-15.
19.   Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood ves 
  sels. Nephrol Dial Transplant 2000;15 Suppl 3:14-8.
20.   Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values  
  in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med   
  1998;339:584-90.
21.   McMahon LP, Mason K, Skinner SL, et al. Effects of haemoglobin normalization on quality of life and  
  cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-30.
22.   Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymp 
  tomatic cardiomyopathy. Kidney Int 2000;58:1325-35.
23.   Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during  
  erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis    
  2000;35:250-6.
24.   Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure. Remodeling  
  and the potential for intervention. Circulation 1993;87:IV90-IV96.
25.   Silverberg DS, Wexler D, Blum M et al. The use of subcutaneous erythropoietin and intravenous iron for  
  the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and  
  renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol  
  2000;35:1737-44.
26.   Horwich TB, Fonarow GC, Hamilton MA, et al.  Anemia is associated with worse symptoms, greater  
  impairment in functional capacity and a significant increase in mortality in patients with advanced  
  heart failure. J Am Coll Cardiol 2002;39:1780-6.
27.   Al-Ahmad A, Rand W.M, Manjunath G et al. Reduced kidney function and anemia as risk factors for  
  mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2003;38:955-62.
28.   McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent  
  risk factors for death among patients with congestive heart failure admitted to community   
  hospitals: A population-based study. Journal of the American Society of Nephrology    
  2002;13:1928-36.
29.   Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated  
  with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.  
  Circulation 2003;107:223-5.
30.   Van der Meer P, van Gilst WH, van Veldhuisen DJ. Anemia and congestive heart failure. Circulation  
  2003;108:E41-E42.Erythropoietin in cardiovascular diseases 31
31.   Iversen PO, Woldbaek PR, Tonnessen T, et al.  Decreased hematopoiesis in bone marrow of mice    
  with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002;282:R166-R172.
32.   Torre-Amione G, Bozkurt B, Deswal A, et al. An overview of tumor necrosis factor alpha and the    
  failing human heart. Curr Opin Cardiol 1999;14:206-10.
33.   Rauchhaus M, Doehner W, Francis DP et al. Plasma cytokine parameters and mortality in patients    
  with chronic heart failure. Circulation 2000;102:3060-7.
34.   Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of    
  severe congestive heart failure. Eur J Heart Fail 2002;4:681-6.
35.   Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to    
  epoetin. Nephrol Dial Transplant 1999;14:1836-41.
36.   Androne AS, Katz SD, Lund L et al. Hemodilution is common in patients with advanced heart    
  failure. Circulation 2003;107:226-9.
37.   Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with    
  moderate to severe chronic heart failure. Circulation 2003;107:294-9.
38.   Silverberg DS, Wexler D, Blum M et al. The effect of correction of anaemia in diabetics and non-   
  diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous    
  erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
39.   Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against    
  experimental brain injury. Proc Natl Acad Sci U S A 2000;97:10526-31.
40.   Olivetti G, Abbi R, Quaini F et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:   
  1131-41.
41.   Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation    
  1997;95:320-3.
42.   Ratajczak J, Majka M, Kijowski J et al. Biological significance of MAPK, AKT and JAK-STAT protein acti   
  vation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 2001;    
  115:194-204
43.   Silva M, Grillot D, Benito A, et al. Erythropoietin can promote erythroid progenitor survival by repress   
  ing apoptosis through Bcl-XL and Bcl-2. Blood 1996;88:1576-82.
44.   Silva M, Benito A, Sanz C et al. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in    
  erythropoietin-dependent progenitor cell lines. J Biol Chem 1999;274:22165-9.
45.   Grimm C, Wenzel A, Groszer M et al. HIF-1-induced erythropoietin in the hypoxic retina protects    
  against light-induced retinal degeneration. Nat Med 2002;8:718-24.
46.   Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor    
  in the developing human fetus. Early Hum Dev 1998;52:235-49.
47.   Van der Meer P, Lipsic E, Boer RA, et al. A functional erythropoietin receptor in a rat heart is linked to    
  anti-apoptotic effects. J Am Coll Cardiol 2003;41:330A. Chapter 2 32
48.   Wu H, Lee SH, Gao J, Liu X, et al. Inactivation of erythropoietin leads to defects in cardiac morphogen 
  esis. Development 1999;126:3597-605.
49.   Amann K, Neimeier KA, Schwarz U et al. Rats with moderate renal failure show capillary deficit in  
  heart but not skeletal muscle. Am J Kidney Dis 1997;30:382-8.
50.   Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial  
  cells. Proc Natl Acad Sci U S A 1994;91:3974-8.
51.   Ashley RA, Dubuque SH, Dvorak B, et al. Erythropoietin stimulates vasculogenesis in neonatal rat mes 
  enteric microvascular endothelial cells. Pediatr Res 2002;51:472-8.
52.   Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in  
  vitro. Kidney Int 1995;47:740-5.
53.   Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic poten 
  tial. Microvasc Res 2002;64:326.
54.   Jelkmann W, Hellwig-Burgel T. Biology of erythropoietin. Adv Exp Med Biol 2001;502:169-87.
55.   De Boer RA, Henning RH, Tio RA et al. Identification of a specific pattern of downregulation in expres 
  sion of isoforms of vascular endothelial growth factor in dilated cardiomyopathy. Heart    
  2002;88:412-4.
56.   Van Veldhuisen DJ, van den Heuvel AF, Blanksma PK, et al. Ischemia and left ventricular dysfunction: a  
  reciprocal relation? J Cardiovasc Pharmacol 1998;32 Suppl 1:S46-S51.
57.   De Boer RA, van Veldhuisen DJ, van der WJ et al. Additional use of immunostaining for active caspase 3  
  and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. J Card  
  Fail 2000;6:330-7.
58.   Shi Q, Rafii S, Wu MHD et al. Evidence for circulating bone marrow-derived endothelial cells.  
  Blood 1998;92:362-7.
59.   Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells    
  responsible for postnatal vasculogenesis in physiological and pathological neovascularization.  
  Circulation Research 1999;85:221-8.
60.   Digicaylioglu M, Bichet S, Marti HH et al. Localization of specific erythropoietin binding sites in  
  defined areas of the mouse brain. Proc Natl Acad Sci U S A 1995;92:3717-20.
61.   Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both  
  safe and beneficial. Mol Med 2002;8:495-505.
62.   Scarabelli T, Stephanou A, Rayment N et al. Apoptosis of endothelial cells precedes myocyte cell  
  apoptosis in ischemia/reperfusion injury. Circulation 2001;104:253-6.
63.   Webster KA, Discher DJ, Kaiser S, et al. Hypoxia-activated apoptosis of cardiac myocytes requires  
  reoxygenation or a pH shift and is independent of p53. J Clin Invest 1999;104:239-52.Part 1: Pathophysiology of AnemiaChapter 3
Levels of hematopoiesis inhibitor
N-acetyl-seryl-aspartyl-lysyl-proline 
partially explain the occurrence of 
anemia in heart failure
Peter van der Meer, Erik Lipsic, B. Daan Westenbrink, Ruud M.A. van de Wal, Edo Vellenga, 
Regien G.Schoemaker, Dirk J. van Veldhuisen, Adriaan A. Voors, Wiek H. van Gilst
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Abstract
Background:  Anemia is common in patients with chronic heart failure (CHF) and is associated 
with a poorer prognosis. However, only a minority of patients with CHF has an impaired renal 
function or underlying hematinic deficiencies. It has been shown that inhibition of renin an-
giotensin system (RAS) is associated with the development of anemia. The aim of the present 
study was to determine possible mechanisms linking anemia to RAS activity in CHF patients. 
Methods and Results:  We initially evaluated 98 patients with advanced stable CHF, treated with 
ACE inhibitors (left ventricular ejection fraction 28±1%, age 69±1 years and 80% male), ten of 
whom had an unexplained anemia (normal hematinics and no renal failure). These 10 anemic 
patients were matched with 10 non-anemic patients based on age and left ventricular ejection 
fraction. Serum ACE activity was 73% lower in anemic CHF patients compared to non-anemic 
CHF patients (p=0.018). Moreover, serum of these patients inhibited in vitro the proliferation 
of bone marrow derived erythropoietic progenitor cells of healthy donors by 17% (p=0.003). 
Levels of the hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), which 
is almost exclusively degraded by ACE, were significantly higher in anemic CHF patients and 
clearly correlated to erythroid progenitor cell proliferation (r=-0.64, p=0.001). 
Conclusions:  Serum ACE activity is markedly lower in anemic CHF patients and serum of these 
patients inhibits hematopoiesis. The clear correlation between Ac-SDKP and proliferation of 
erythroid progenitor cells suggests an inhibitory role of Ac-SDKP on hematopoiesis in CHF 
patients, which may explain the observed anemia in patients treated with ACE inhibitors.
Background
Anemia is present in a substantial part of the chronic heart failure (CHF) population, rang-
ing from 14-55%, depending on the definition of anemia and severity of disease.1 Lower 
hemoglobin levels are also independently associated with an impaired prognosis2-5, but the 
cause of anemia in CHF is often unknown. A recent study in the UK demonstrated that only 
a minority of CHF patients had renal impairment or underlying hematinic deficiencies.6 This 
was confirmed by Witte et al, who showed that less than one third of the CHF patients were 
iron, folate or vitamin B12 deficient.7 Therefore, other factors may be involved in the origin 
of anemia in CHF. 
Since the early 1980’s, it has been demonstrated that the use of angiotensin-converting en-
zyme (ACE) inhibitors is associated with lower hemoglobin levels.8,9 Possible mechanisms 
might be related to changes in the renin angiotensin system (RAS). In vitro, angiotensin II 
stimulated the proliferation of erythroid-progenitor cells, an effect inhibited by angiotensin 
II receptor blockers.10 Furthermore, it has been shown that N-acetyl-seryl-aspartyl-lysyl-pro-
line (Ac-SDKP), a strong inhibitor of hematopoietic stem cells, was found to be hydrolyzed 
almost exclusively by ACE. Indeed, ACE inhibitors markedly increased Ac-SDKP levels by 5-6 
fold, and may therefore reduce hematopoietic activity.11
The aim of the present study was to determine possible mechanisms linking anemia to RAS 
activity in CHF patients. Accordingly, we evaluated the different components of the RAS and 
studied the effect of serum of anemic CHF patients on the proliferation of erythroid progeni-
tor cells and compared this to non-anemic CHF patients and healthy controls.Serum of CHF patients inhibits erythropoiesis 39
Figure 1 Comparison of the effect of serum on the formation of burst-forming units-erythroid (BFU-E), as a percent-
age of the baseline value (incubation without serum) in anemic, non-anemic and healthy controls. Boxplot show 
the median with 25-75% range of the BFU-E colonies present in culture.
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Figure 2 Levels of Ac-SDKP in anemic, non-anemic and healthy controls. Boxplot show the median with 25-75% 
range of Ac-SDKP in nmol/L.
Methods
Patients
In order to identify the patients with anemia of unknown origin, 98 consecutive patients 
with advanced systolic CHF were evaluated at our outpatient clinic, between February 2003, 
and November 2003. In all patients CHF was diagnosed on the basis of symptoms and the 
presence of left ventricular enlargement or systolic functional impairment by radionuclide 
ventriculography or echocardiography, according to the European Society of Cardiology 
Guidelines.12 All patients had a left ventricular ejection fraction (LVEF) <45% and all pa-
tients were in New York Heart Association (NYHA) functional class III. Patients were stable 
on medication for at least three months and all patients were treated with an ACE inhibitor. 
The dose of the ACE inhibitor is expressed as a percentage of the recommended dose.12 
Patients using an angiotensin receptor blocker (ARB) or patients with myocardial infarction Chapter 3 40
(within 12 weeks), malignant or inflammatory diseases were excluded from this study. 
To evaluate the hematopoietic response in patients without CHF, we included 8 healthy con-
trols, without anemia and clinical signs of inflammation or CHF. The study was approved by 
the institutional review board and all patients provided written informed consent.
Hormonal measurements
Venous blood samples were taken at the outpatient clinic while the patient was in upright 
position. The blood samples were centrifuged and stored at –80°. Serum samples were 
thawed and analyzed immediately. High sensitive C-reactive protein (hs-CRP) was measured 
by nepholometry (BNII N; Nade Behring, Marburg, Germany), ACE activity by enzymatic 
assay (Bühlmann Laboratory AG, Schünenbuch, Switzerland), and TNF-α by immunoassay 
(R&D System, Minneapolis, USA). Ac-SDKP levels were determined by competitive enzyme 
immunoassay (Caymann, Ann Arbor, USA). In the plasma samples, N-Terminal pro-brain 
natriuretic peptide (NT-proBNP) was measured by immunoassay (Roche Diagnostics, Basel, 
Switzerland), erythropoietin (EPO) by immulite EPO assay (DPC, Los Angeles, USA) and an-
Table 1. Baseline characteristics of the total population
Variable
Anemic
(n=17)
Non anemic
(n=81)
Total Population
(n=98)
p-value
Hemoglobin levels (g/dl)     11.7 ± 0.2      13.9 ± 0.2    13.6 ± 0.2 -
Age (years)   72 ± 3  68 ± 1  69 ± 1  0.16
LVEF (%)    31 ± 3  28 ± 1   28 ± 1  0.33
Male sex (% male)     94     77     80 0.11
Ischemic etiology (%)     77     63     66    0.30
SBP (mmHg) 114 ± 3 125 ± 2 123 ± 2    0.02
NT-proBNP (pmol/L) 160 [80-231] 97 [33-244] 110 [49-239]   0.38
GFRc (ml/min)   54 ± 5   67 ± 3     64 ± 2    0.05
Serum Iron (µmol/L)   16.1 ± 1.3     16.0 ± 0.8   16.0 ± 0.7    0.94
Iron Saturation (%)    27.3 ± 3.4   23.8 ± 1.3   24.5 ± 1.2 0.26
Ferritin (µg/L)    111 ± 23    118 ± 10  116 ± 9      0.78
Folate (nmol/L)   12.2     12.0    12.0   0.90
Vitamin B12 (pmol/L)   261 ± 35   318 ± 19  307 ± 17    0.20
Medication (% use)
ACE inhibitor  100 100 100 -
Beta Blocker 77 71 72   0.64
Diuretics 94 92 93  0.81
ACE genotype (%)   0.46
D/D+I/D 70.1 79.0   77.9
   I/I
29.4 21.0 22.1
LVEF= left-ventricular ejection fraction. SBP= systolic blood pressure. NT-proBNP= N-terminal pro-brain natriuretic 
peptide. GFRc= estimated glomerular filtration rate. ACE= angiotensin-converting enzyme, p-value = anemic vs. non-
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giotensin II levels by specific radioimmunoassay, as previously described.13 All analyses were 
performed according to the manufacturer’s guidelines. 
Renal function and anemia
The glomerular filtration rate (GFR) is a standard indicator of renal function. Under steady-
state conditions, GFR is estimated from serum creatinine using a formula that accounts for 
the influence of age and body weight on creatinine production, the Cockroft Gault equa-
tion: GFRc=[140-age in years)x(body weight in kg)]/(72xserum creatinine in mg/dL).14 
In women, the value is multiplied by 0.85. This formula is commonly used in several stud-
ies of CHF and renal function.15,16 Anemia was defined according to the general accepted 
definition of the World Health Organization (hemoglobin ≤12 g/dL for women, ≤13 g/dl 
for men).
Hematopoiesis assay
Bone marrow cells of healthy donors were used for the in vitro burst-forming unit-erythroid 
(BFU-E) assay. Bone marrow mononuclear cells (BM-MNC) were isolated by Ficoll-Paque 
gradient centrifugation. Cells were collected, washed and resuspended in methylcellulose 
medium (Stemcell technologies Inc, Vancouver, Canada) with 2 U/ml recombinant-human 
EPO and 10% of serum of either anemic CHF patients, non-anemic CHF patients, healthy 
controls or without additional serum. All BFU-E assays were performed in quadruple. Blinded 
for sub-group allocation, BFU-Es were counted after 14 days of incubation. The number of 
BFU-E colonies in the absence of additional serum was considered to be the baseline value, 
and the number of BFU-E colonies was expressed as a percentage from baseline.
Genetic analysis
Genomic DNA was extracted from white blood cells. The ACE fragment containing the Inser-
tion (I) / Deletion (D) sequence was detected by Polymerase Chain Reaction using oligo-
nucleotide primers flanking the ALU insertion, as previously described.17 Due to insufficient 
DNA extraction, in one patient no ACE I/D polymorphism could be determined.
Statistics
Data are given as mean ± SEM when normally distributed, as median and interquartile range 
(IQR) when skewed distributed and as frequencies for categorical variables. We compared 
differences between groups with the Student’s t-test, Mann-Whitney U, or the ANOVA, with 
Fisher’s protected LSD post-hoc analysis, where appropriate. Correlations between variables 
were expressed with the Pearson or Spearman correlation coefficient, where appropriate. We 
considered p-values below 0.05 as statistically significant. For all statistical analysis SPSS ver-
sion 11.0 was used.
Results
Baseline characteristics of the total population are shown in table 1. The average age of the 
patients was 69±1 years, 80% were men, and the average LVEF was 28±1%. Mean hemo-
globin levels were 13.6 g/dL (range 10.1-16.8 g/dL, median 13.6 g/dL). According to the 
WHO definition 17 of the 98 (17.3%) CHF patients were anemic. Anemia was associated Chapter 3 42
with lower calculated GFR (p=0.049) and lower systolic blood pressure (p=0.02), possibly 
reflecting hypoxia induced vasodilation. When log(EPO) was plotted as a function of hemo-
globin, we observed only a weak non-significant correlation (r=-0.06, p=0.59). 
We found that 4 of the 17 (24%) anemic CHF patients were vitamin B12 deficient [reference 
range: 170-750 pmol/L], one patient had low ferritin levels [reference range: 36-234 μg/L], 
and no folate acid deficiencies were observed [reference range: 4-30 nmol/L]. Two patients 
(12%) had a calculated GFR below 30 ml/min. 
In the majority of anemic CHF patients (59%, n=10), no explanation for their anemia was 
found. We matched these 10 anemic patients with 10 non-anemic patients based on age 
and severity of heart failure (LVEF). Serum of anemic CHF patients inhibited the formation 
of BFU-Es by 17% compared to non-anemic CHF patients (p=0.003, figure 1). There was 
no difference in BFU-E formation between healthy controls and non-anemic CHF patients 
(p=0.48, figure 1). The anemic and non-anemic CHF patients were similar with regard to 
levels of angiotensin II, EPO, NT-proBNP, hs-CRP, TNF-α and GFRc, as well as duration and 
dose of ACE inhibitor use (table 2). However, ACE activity was 73% higher in the non-ane-
mic, compared to anemic CHF patients (p=0.017; table 2). Consequently, Ac-SDKP levels 
were significantly higher in the anemic CHF patients compared to non-anemic CHF patients, 
whereas healthy controls had the lowest Ac-SDKP levels (figure 2). In addition, there was a 
strong correlation between Ac-SDKP levels and BFU-E formation (r=-0.64, p=0.001). 
Regarding the ACE I/D polymorphism, patients homozygous for the I-allele were present 
only in the anemic sub-group (table 2, p=0.07). Furthermore, the ACE I/D polymorphism 
was related to BFU-E formation. Patients homozygous for the I-allele showed significant 
lower proliferation of erythroid progenitor cells compared to patients with DD or ID geno-
types (p=0.046 and p=0.026, respectively).
Discussion
In the present study we show for the first time that CHF patients without identifiable cause 
of anemia have lower ACE activity and their serum inhibits the proliferation of bone marrow 
derived erythropoietic cells. We found that levels of Ac-SDKP, a strong hematopoiesis inhibi-
tor, were significantly higher in these anemic CHF patients. Since ACE is the principle enzyme 
metabolizing Ac-SDKP, this links ACE activity to lower hemoglobin levels.
The decline of hemoglobin levels with ACE inhibitor use has been observed in numerous 
patients populations  18-21 as well as healthy volunteers.22 Furthermore, ACE inhibitors are 
successfully used in the treatment of post-transplant polycythemia18 and in subjects with al-
titude polycythemia.20 These effects were also observed in CHF patients. A recent substudy of 
the Studies Of Left Ventricular Dysfunction (SOLVD), demonstrated convincingly that enala-
pril significantly increased the odds of developing anemia by 56% in patients with CHF.23 
The reduction in hematocrit levels occurs within several months after the start of enalapril 
and is sustained for at least several years. However, the observed effect on hematocrit seems 
to be modest and might only affect a selected population. In addition, ACE inhibitor use was 
associated with a better survival even after adjusting for episodes of anemia and in patients 
with prevalent anemia.23   
Various mechanisms might play a role in the negative effects of ACE inhibitors on hema-
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probably by inhibiting angiotensin II formation.24,25 Recently, Ac-SDKP a natural inhibitor 
of pluripotent hematopoietic stem cell proliferation has been found to be associated with 
ACE inhibitor therapy. Ac-SDKP is a tetrapeptide that reversibly prevents the recruitment of 
hematopoietic stem cells into S phase of the cell cyclus, by maintaining them in G0 phase.26 
This tetrapeptide was found to be degraded almost exclusively by ACE, which can be blocked 
by ACE inhibitors.27 Already a single dose of the ACE inhibitor captopril resulted in a 5.5 
fold increase in the levels of Ac-SDKP.11 In our study we found that Ac-SDKP levels were two 
times higher in anemic CHF patients. This was associated with a marked lower ACE activity 
in anemic compared to non-anemic CHF patients. The observed differences in ACE activity 
and therefore Ac-SDKP levels might be related to the ACE I/D genotype. We observed a lower 
hematopoietic activity in CHF patients homozygous for the ACE I-allele, which is linked to 
lower ACE activity. This is in line with previous findings of Varagunam et al, who showed that 
dialysis patients with the ACE ID/II genotypes, required significant higher dosages of human 
Table 2. Baseline characteristics of the subpopulation
Variable Anemia (n=10) Non-anemia (n=10) P-value
Hemoglobin levels (g/dl)   11.5 ± 0.3   14.9 ± 0.3 -
Age (years) 68 ± 3   70 ± 4 -
LVEF (%)  33 ± 4   33 ± 3 -
Male sex (n)    8     9  0.53
Ischemic etiology (n)    7     7   1.00
SBP (mmHg) 115 ± 4 140 ± 7    0.005
cGFR (ml/min)  61 ± 5   72 ± 9  0.32
Erythropoietin (mU/ml)   15.5 ± 2.7   19.0 ± 3.4 0.43
NT-proBNP (pmol/L) 83 [38-161]   96 [57-313] 0.55
Angiotensin II (pmol/L)       10.1 [4.2-23.4] 13.0 [4.3-54.9] 0.74
ACE activity (U/L)      13.7 [11.3-21.4]    23.8 [18.9-61.2]   0.017
hs-CRP (mg/L)          3.1 [1.8-7.3]  4.6 [1.1-11.0] 0.53
TNF-α (pg/mL)          1.5 [1.0-2.5] 2.0 [1.0-3.6] 0.52
Medication (% use)
 ACE inhibitor  100 100            -
Duration of ACEi use (months)              23 [8-46]             43 [8-46]         0.22
% of recommended dose ACEi         50 [44-100]          63 [25-100]         0.75
Beta Blocker 90 70         0.48
 Diuretics 90 90         1.00
ACE genotype (%) 0.07
D/D + I/D 70 100
 I/I 30 0
SBP= systolic blood pressure. LVEF= left-ventricular ejection fraction. NT-proBNP= N-terminal pro-brain natriuretic 
peptide. GFRc= estimated glomerular filtration rate. TNF= tumor necrosis factor. Hs-CRP= high-sensitivity C-reactive 
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recombinant EPO for the treatment of their renal anemia, compared to the patients homo-
zygous for the D-allele.28 
Several studies found a clear correlation between renal function and Ac-SDKP levels.29 Comte 
et al found that besides degradation by ACE, Ac-SDKP is partially eliminated in the kidney.30 
We found that GFRc was lower in anemic CHF patients compared to non anemic CHF pa-
tients, which might have influenced Ac-SDKP levels. The clinical relevance of Ac-SDKP levels 
was further explored by Le Meur et al, who studied the relation between Ac-SDKP levels and 
the weekly dose of recombinant human EPO for the treatment of renal anemia.29 They ob-
served that dialysis patients required significantly more recombinant human EPO when their 
Ac-SDKP levels were higher, indicating an inhibitory effect of Ac-SDKP on hematopoiesis.       
 A study of Mrug et al showed that angiotensin II levels stimulate the proliferation of he-
matopoietic cells through activation of the angiotensin II type I receptor, this effect was 
abolished by addition of an angiotensin-receptor blocker (ARB).10 One may speculate that 
ACE inhibitors lower angiotensin II levels and therefore inhibit the hematopoietic prolifera-
tion. In our study we included only patients using ACE inhibitors, without concomitant use 
of angiotensin receptor blockers. Since there were no significant differences in angiotensin 
II levels between anemic and non-anemic CHF patients, our study does not suggest a major 
contribution of angiotensin II levels in the observed decreased hematopoietic activity in CHF 
patients. However, because patients receiving ARB were not included in our study we are un-
able to draw conclusions on the possible effect of angiotensin II on hematopoiesis in CHF 
patients. Studies in larger groups of patients, also comparing the effects of ACE inhibitor and 
ARB treatment, should address this issue. 
Several limitations have to be acknowledged. Hemodilution might have influenced the de-
gree of anemia, although all patients were stable on medication for at least three months. 
Inflammation in patients with CHF might lower hemoglobin levels and induce anemia.31 
Inflammatory parameters measured in our study were not different in anemic and non-ane-
mic CHF patients. However other pro-inflammatory cytokines might play a role in the patho-
genesis of anemia in CHF. Furthermore, due to the relatively small sample size one should 
be cautious interpreting the link between the ACE I/D polymorphism and hematopoiesis. 
Studies analyzing larger groups of patients should clarify the possible relationship between 
anemia and ACE genotype in CHF patients. Because of these limitations, we regard our study 
mainly as hypothesis generating. 
In summary, ACE activity of CHF patients without an identifiable cause of anemia is signifi-
cantly lower compared to non-anemic CHF patients, and serum of these patients inhibits he-
matopoiesis. The correlation between Ac-SDKP and proliferation of erythropoietic progenitor 
cells suggests an inhibitory role of Ac-SDKP in hematopoiesis, linking the renin angiotensin 
system to hematopoiesis in CHF patients. 
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Abstract
Objectives:  This study aimed to investigate the prognostic importance of plasma erythropoi-
etin (EPO) levels in Chronic Heart Failure (CHF) patients.
Background:  Anemia is common and associated with an impaired survival in patients with 
CHF. EPO is a hematopoietic growth factor, upregulated in anemic conditions. Little is known 
about the pathophysiology of anemia in CHF and the prognostic importance of plasma EPO 
levels in CHF patients. 
Methods:  In 74 patients with CHF (age 61±2 years, Left Ventricular Ejection Fraction (LVEF) 
0.31±0.01, peak oxygen consumption (VO2) 19.1±0.6, (mean±SEM) and in 15 control pa-
tients, hemoglobin levels and plasma concentrations of EPO and BNP were measured. 
Results:  During a mean follow-up of 3.0 years (range 2.3-5.3), 22 patients (30%) died. 
Anemia was present in 24% of the patients. Multivariate analysis showed that plasma EPO 
(p=0.026) and hemoglobin levels (P=0.005) were independent predictors of survival in this 
CHF population.  We observed only a mild inverse correlation between the logarithm of EPO, 
log(EPO), and hemoglobin levels (r2=0.08, p = 0.02) in CHF patients, whereas the control 
group showed a clear significant inverse correlation (r2=0.44, p=0.007). 
Conclusion:  Elevated plasma EPO levels are associated with an impaired prognosis independent 
of hemoglobin levels and other established markers of CHF severity. Furthermore, in the CHF 
patients, EPO levels poorly correlate with the Hb levels, in contrast to the control group
Introduction
Anemia is commonly observed in patients with CHF (1-3). One of the first studies published 
on anemia and CHF, showed in 142 patients with CHF, that mean hemoglobin (Hb) concen-
tration decreased from 13.7 g/dl in mild CHF to 10.9 g/dl in severe CHF (4). Several other 
studies have also examined the prognosis of anemia in patients with CHF (2;3). Hb levels < 
12.3 g/dl are associated with worsened symptoms, and impaired survival. Although large 
studies have confirmed these finding, the origin of anemia in CHF remains unclear (5). 
In general, in response to anemia, the kidneys produce erythropoietin (EPO), which in turn 
stimulate red blood cell production (6;7). Previous studies already showed that patients with 
CHF exhibit elevated levels of EPO (8;9), although the significance of this finding has still to 
be elucidated. In addition, EPO levels may be correlated with the severity of CHF(8). There-
fore, we hypothesized that elevated EPO levels are associated with a poorer prognosis. In the 
present study, we aimed to establish the prognostic value of both EPO and Hb on mortality 
in CHF patients.  
Materials and methods
Patients
The prognostic values of EPO and Hb levels were retrospectively assessed in 74 Caucasian CHF 
patients with stable, mild to advanced CHF consecutively admitted to our center (a tertiary 
referral center), between 1998 and 2000. Referral of patients to our clinic was by general 
practitioners, cardiologists, local hospitals or other units of our hospital. Patients were treated 
for heart failure at the outpatient clinic. Patients were stable on medication for at least 3 
months.  In all patients, CHF was diagnosed on the basis of standard criteria, and presence of Erythropoietin and survival in heart failure 51
left ventricular enlargement or systolic functional impairment by radionuclide ventriculog-
raphy or echocardiography, according to the European Society of Cardiology guidelines(10). 
Patients with isolated diastolic dysfunction, valvular disease, myocardial infarction (within 
12 weeks), cerebrovascular accident (within 12 weeks) or severe renal failure (creatinine 
>220 μmol/L) were excluded. To evaluate the EPO response in patients without CHF, we 
included 15 patients, referred to our center with complaints of chest pain or palpitations. 
Control patients had a mean age of 50.1±4.5 years and had a normal left ventricular function 
(LVEF ≥ 0.60), normal renal function, no clinical signs of inflammation and no evidence of 
CHF. All subjects gave informed consent for the protocol, which was approved by the local 
Medical Ethics Committee. Follow-up data were obtained by review of the medical record or 
telephone. The primary end point of the study was all-cause-mortality. No cardiac transplanta-
tions were observed in this population.
 Measurement of BNP and EPO levels
Venous blood samples were taken in the morning to avoid circadian influences. Plasma was 
stored at -80°C, and BNP concentrations were determined with an immunoradiometric assay 
(Shionoria, Osaka, Japan). Plasma EPO levels were measured using the IMMULITE® EPO assay 
(DPC, Los Angeles, CA), which has been described before (11). The DPC assay consists of a li-
gand-labeled monoclonal anti-EPO capture antibody, an alkaline phosphatase-labeled polyclonal 
conjugate antibody, and solid-phase anti-ligand-coated polystyrene beads. The amount of plasma 
EPO was quantified by chemiluminescent measurement in a luminometer. The assay showed an 
intra-assay variability of less than 1%. The impact of age and gender on plasma EPO levels was 
limited and not significant. 
Renal Function
The glomerular filtration rate (GFR) is a standard indicator of renal function. Under steady-
state conditions, GFR is estimated from serum creatinine using a formula that accounts for 
the influence of age and body weight on creatinine production (the Cockroft Gault equation) 
GFR:[140-age in years)x(body weight in kg)]/(72xserum creatinine in mg/dL) (12). In 
women, the value is multiplied by 0.85. This formula is validated and used in several studies 
of CHF and renal function(13;14).
Statistics
Data are given as mean ± SEM and as frequencies for categorical variables. We included the 
following risk factors in our analysis: sex, age, history of hypertension, history of diabetes, 
etiology of the CHF, left ventricular end diastolic dimension (LVEDD), GFRc, sodium levels, 
concomitant medication and severity of CHF, assessed by BNP-levels, LVEF and VO2. Kaplan 
Meier method was used to study the influence of several baseline clinical and biochemical 
variables on survival in the study population. The variables with p < 0.05 in the univariate 
analysis were used in the multivariate analyses with the use of the Cox backward Wald regres-
sion analysis. Hazard ratios (HR) with 95% confidence intervals (CI) demonstrate the risk 
of death. Pearson and Spearman correlation coefficients were calculated to determine which 
clinical and biochemical variable had an univariate correlation with log(EPO). All reported 
probability values were 2-tailed, and a p-value <0.05 was considered statistically significant. 
For all statistical analysis SPSS version 11.0 was used.Chapter 4 52
Results
Patient characteristics 
The cohort was 80% male, and age ranged from 26 to 90 years. The NYHA functional class II, 
III and IV comprised 37%, 32% and 31% respectively. Other baseline characteristics are given 
in table 1. Of the 74 patients, 22 (30%) died after 16 to 1728 days (mean 621 days), 77.8% 
of them had a cardiovascular cause of death. Mean follow-up period of the 52 survivors was 
1100 days (range 844 – 1934, median 987). 
Table 1.   Baseline Characteristics
Variable
Total cohort
(n=74)
Survivors 
(n=52)
Non-Survivors 
(n=22)
p-value
Age (years)     60.9 ± 1.7           59.3 ± 2.0        64.5±3.4   0.15
Sex (% male)       73.0         78.9       59.1     0.08
NYHA (%)      0.001
Class II   36.5   48.1       9.1
Class III   32.4      36.5    22.7
Class IV   31.1        15.4  68.2
Ischemic etiology (%)      47.3             46.2       50.0        0.76
History of hyptertension (%)     40.6        36.7       50.0       0.31
History of diabetes (%)        12.2     11.5           13.6         0.80
LVEF (%)               0.31± 0.01       0.33 ± 0.02     0.26 ± 0.02               0.035
VO2 (ml kg-1min-1)        19.1 ± 0.6        20.4 ± 0.7   16.1 ± 1.0     0.001
Calculated GFR (ml/min)         76.0 ± 3.5     79.5 ± 4.0   67.0 ± 6.8         0.10
BNP (pmol/L)      109.9 ± 13.5       80.6 ± 12.9    179.1 ± 29.3       0.002
Sodium (mmol/L)       137.6 ± 0.3      137.8 ± 0.4     137.4 ± 0.7          0.58
Erythropoietin levels (mU/mL)         19.4 ± 1.5     16.8 ± 1.3      25.8 ± 3.8     0.033
Hemoglobin levels (g/dL)      13.9 ± 0.2       14.2 ± 0.2   13.3 ± 0.2   0.013
Left Atrial Diameter (mm)      63.6 ± 1.5      62.7 ± 1.7       65.6 ± 2.8           0.36
LV End Systolic Diameter (mm) 49.0 ± 1  47.0 ± 2   53.0 ± 2                  0.027
LV End Diastolic Diameter (mm)     60 ± 1 59.0 ± 1 62.0 ± 2           0.28
Medication (% use)
Ace-inhibitor    81.1      71.2    90.9  0.16
Beta Blocker     67.6      71.2  59.1 0.21
Diuretics    63.5     53.8    86.4        0.009
Aldosteron antagonist     27.0  24.1   39.1  0.24
Nitrates     18.9      13.5     31.8  0.07
Digoxine     27.0     23.1    36.4  0.24
LVEF= left ventricular ejection fraction. VO2=peak oxygen consumption. LV= left ventricular. ACE= angiotensin covert-
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Hb and EPO levels
Mean Hb levels were 13.9 g/dL (range 10.6-17.6 g/dl, median 13.8 g/dL). When we used 
the generally accepted definition of the World Health Organization (hemoglobin ≤12 g/dL 
for women, ≤13 g/dl for men), we found that 24.3% of the CHF patients were anemic. 
Non-survivors had lower Hb levels (p<0.05) and higher plasma EPO levels than survivors 
(p<0.05). When log(EPO) was plotted as a function of Hb, only a modest inverse correlation 
(r2=0.08, p = 0.02) was observed in CHF patients (fig 1a). To compare the EPO response 
in non-CHF patients, we obtained blood samples from 15 control patients. Interestingly, we 
found a clear, significant inverse correlation between log(EPO) and Hb in the control patients 
(r2=0.44, p = 0.007) (fig 1b). 
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Figure 1a  Correlation between log(EPO) and hemoglobin in the CHF cohort. Figure 1b  Correlation between log(EPO)         
and hemoglobin in the control patients.
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Furthermore, a modest but statistically significant correlation was observed between plasma 
EPO levels and the severity of CHF, assessed by BNP levels (r2=0.14, p < 0.001), NYHA-class 
(r2=0.09, p=0.01) and VO2 (r2=0.09, p=0.01). There was no significant correlation between 
EPO levels and LVEDD and LVEF, r2=0.003 and r2=0.04, respectively.  Use of medication, 
including ACE-inhibitors, betablockers and diuretics, was not significantly correlated to Hb 
or EPO levels.  
Relationship of Hb and EPO with mortality
Kaplan-Meier survival curve clearly demonstrate increased mortality in patients with anemia, 
HR 3.28 [95% CI; 1.31-8.18, p = 0.01]  (fig 2). Patients with anemia had a two year mor-
tality rate of 33 %, compared with 14% for non-anemic patients. Furthermore, also elevated 
EPO levels (≥ 22.6 mU/mL) are associated with an impaired outcome, HR 2.6 [95% CI; 
1.05-6.44, p = 0.04] (fig 3). Two-year mortality rates were 32% in those with high EPO 
levels (≥22.6 mU/mL), compared with 16% for those with low EPO levels (<22.6 mU/mL). 
After adjustment for possible confounders, both Hb and EPO levels remained independently 
associated with an increased mortality (table 2). 
Discussion
This is the first study to examine the prognostic value of EPO levels in CHF patients. Our 
findings demonstrate that increased plasma EPO levels predict an impaired medium to lon-
ger-term survival in patients with CHF. Furthermore, as previously described, lower Hb levels 
were also associated with increased mortality(2). However, EPO and Hb were both indepen-
dent prognostic markers. When the correlation between EPO and Hb was further studied in 
CHF patients and compared with controls, we observed an inadequate increase in EPO levels 
relative to the hemoglobin levels.  
We found that 24% of the CHF patients were anemic, according to World Health Organiza-
tion criteria and Hb levels were an independent predictor of all-cause mortality.  These find-
ings are well comparable with others studies, which show that anemia is associated with an 
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impaired survival in patients with CHF (3;5;15). A recent study of Horwich et al. also showed 
that anemia was common in patients with advanced heart failure (NYHA class III and IV) and 
patients with NYHA class IV were more likely to have lower Hb levels(2). They also showed 
that Hb levels <12.3 g/dL were associated with an impaired survival in patients with ad-
vanced chronic heart failure. However, the prognostic value of Hb levels in new cases of heart 
failure seems to be limited(16). None of these studies assessed the role of endogenous EPO 
levels in CHF patients.
We observed that elevated plasma EPO levels were associated with severity of CHF.  This 
finding has previously been reported by two other groups (8;9). However, we are the first 
to show that elevated EPO levels are a prognostic marker for impaired survival in the CHF 
population. Furthermore, elevated plasma EPO was a risk factor independent of Hb levels. 
To further elucidate the effect of EPO on Hb levels in CHF patients, we correlated log(EPO) to 
Hb levels. Interestingly, we found only a very modest inverse correlation between log(EPO) 
and Hb levels in CHF patients, while there was a clear correlation in the control group. These 
findings may indicate a blunted EPO response relative to the Hb levels. This mechanism has 
already been proposed by others, who suggest that resistance to EPO in the bone marrow 
may explain the anemia observed in CHF patients(17).
From the modest correlation between EPO and Hb in CHF patients, we hypothesize that 
sensitivity to EPO may be insufficient in CHF patients. Therefore one might assume beneficial 
effects of EPO treatment in CHF patients(18). Several studies already indicated the positive 
effects of EPO treatment in CHF patients (4;19;20). A study of Silverberg showed that the 
treatment of anemia in patients with severe CHF, with EPO and intravenous iron, improved 
cardiac function and quality of life, and markedly reduced hospitalization(19). Another 
group observed that EPO treatment in NYHA class III-IV patients, enhanced exercise capacity 
and also improved quality of life(20). These studies showed that EPO treatment is both safe 
and beneficial in anemic CHF patients. 
The main limitation of this study was its relatively small size (74 patients, 22 events). Fur-
thermore, we did not measure cytokine levels, which may influence the effect of EPO on Hb 
levels. We measured EPO and Hb levels on a single point and thus can only speculate on its 
importance over time. Because of these limitations, we regard our study mainly as a hypoth-
esis-generating study.  Nevertheless, our findings suggest that lower Hb levels and elevated 
EPO levels are both independently associated with an impaired survival in CHF patients.
Table 2.   Univariate and multivariate predictors of all-cause mortality. 
Variable Univariate Multivariate
HR CI p HR CI p
LVEF (%)   0.960 0.920-1.001   0.059 -  - -
BNP (pmol/L)   1.006   1.003-1.009     0.001 -  - -
Hb (g/dL) 0.463    0.278-0.773    0.003  0.408  0.219-0.759 0.005
EPO (mU/mL)  1.042   1.015-1.070    0.002  1.034  1.004-1.064 0.026
Age (years)  1.025 0.994-1.056 0.110 1.031 0.999-1.065 0.056
GFRc (ml/min)  0.984  0.965-1.003     0.096 -  - -Chapter 4 56
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Abstract
Background:  Recent studies show that erythropoietin (EPO) plays a protective role in brain 
ischemia. In this condition, administration of EPO protects neurons from ischemic damage. 
Recently, it has been shown that in patients with chronic heart failure (CHF), EPO treatment 
improved cardiac function. In the present study we assessed the role of EPO and EPO-recep-
tor (EPO-R) in the heart.
Methods and Results:  We studied the presence and functionality of the EPO-R in isolated rat 
hearts in the Langendorff set-up. Hearts were perfused for 20 minutes with 10 U/ml EPO 
or vehicle.  Immunohistochemistry revealed the presence of the EPO-R on endothelial cells, 
fibroblasts and to a lesser extent cardiomyocytes. Furthermore, perfusion with EPO resulted 
in a 50% increase in the phosphorylated MAP kinases p42/p44. To evaluate the protective 
role of EPO in cardiac ischemia, we performed low-flow (0.6 ml/min) ischemia/reperfu-
sion experiments in isolated rat hearts. Administration of EPO (10 U/ml) reduced the cel-
lular damage by 56% (p<0.05) during reperfusion, diminished apoptosis by 15% (p<0.05) 
and resulted in a significantly improved recovery of left ventricular pressure (p=0.02) and 
coronary flow (p=0.01).
Conclusion:  The present data suggest that a functional EPO-R is present in rat adult cardiac 
tissue and that exogenous EPO administration improves cardiac function after ischemia/re-
perfusion injury.
Introduction
In response to ischemia, mammalian cells express a variety of proteins, including Eryhtro-
poietin (EPO) and Vascular Endothelial Growth Factor (VEGF)(1).  The regulation of these 
two proteins is mediated by hypoxia inducible factor 1 (HIF-1). Expression of HIF-1 in-
creases exponentially, as cellular O2 concentrations decrease(1;2). Erythropoietin (EPO) is 
a glycoprotein hormone, primarily produced in the kidney. It mediates the physiological 
response to hypoxia by increasing red blood cell production. However, expanding evidence 
suggests that EPO plays also major role in non-erythropoietic processes. 
Several reports showed its efficacy in brain and retinal diseases (3-5). A study in rats sub-
jected to cerebral ischemia showed a significant reduction in brain infarct size(5;6). Speci-
ficity and biological relevance of these changes were demonstrated by the observation that 
neutralization of endogenous EPO with soluble EPO-R augments ischemic brain damage(7). 
During ischemia, the EPO-receptor (EPO-R) is locally upregulated in brain tissue (8). After 
binding with its receptor, EPO signals through various intracellular pathways, including the 
MAP p42/p44 and JAK2-STAT5 tyrosine kinases (9). It was recently shown that activation of 
these pathways by EPO resulted in anti-apoptotic effect in various tissues including, brain, 
retinal cells and erythroide precursor cells(3;10;11).  
Little is known about the presence and protective role of EPO and its receptor in the heart. 
Juul et al  have described the presence of EPO and EPO-R in human fetal cardiac tissue (12). 
Experiments with knock-out mice, deficient for the genes expressing EPO and EPO-R, pro-
vide more evidence for its role in cardiac tissue, as both EPO-/- and EPO-R-/- mice suffer from 
ventricular hypoplasia and abnormalities in the vascular network (13). Silverberg et al have 
shown that EPO treatment, in patients with CHF, results in an increased left ventricular ejec-Erythropoietin induces ex-vivo cardioprotection 65
tion fraction, as compared with the placebo control group and there is a growing interest in 
this subject in the last few years (14;15). 
The present study was designed to examine the presence and functionality of the EPO-R in 
adult cardiac tissue. In addition, we evaluated the protective effects of exogenous EPO admin-
istration in ischemia/reperfusion injury in the isolated rat heart.
Methods
Study design
Langendorff experiments were performed in isolated rat hearts that were perfused with EPO 
(10 U/ml) or vehicle for 20 minutes. These hearts were used to determine the expression 
and localization of EPO-R, and common signaling pathways were explored. To determine the 
protective effects of EPO treatment on ischemia/reperfusion injury, we studied 2 experimen-
tal groups (each consisting of 6 rats): ischemia/reperfusion without EPO and ischemia/re-
perfusion with EPO. 
Langendorff perfusion:
This well established experimental set-up has been described earlier (11;16-19). In short, 
rats were anaesthetised with isoflurane in O2/N2 and 500U of heparin was injected in the 
tail vein. The heart was rapidly excised and the aorta was immediately perfused retrogradely 
by a modified Tyrode solution (glucose 10, NaCl 128.3, KCl 4.7, NaHCO3 20.2, CaCl2, 1.35, 
NaH2PO4 0.42, MgCl2, 1.05; all mmol/liter) and was equilibrated with 95% O2 and 5% CO2. 
Perfusion pressure was maintained at 60mmHg. Coronary flow (CF) was measured by a 
microprocessor, which controlled the perfusion pressure by adjusting a peristaltic perfusion 
pump. CF and left ventricular peak pressure were monitored continuously. After equilibrating 
for 15 minutes, hearts were subjected to low flow ischemia (0.6ml/min) for 40 minutes, 
followed by a 2 hours reperfusion period at a constant 60mmHg perfusion pressure. EPO 
(10U/ml) or vehicle was administered from stabilization throughout the protocol. All the 
experiments conform with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutions of Health.
Analysis of coronary effluent
During stabilization (t=5 minutes), ischemia (t=20, t=30 and t=54 minutes) and reperfu-
sion (t=55, t=56, t=57, t=60, t=70, t=90, t=120 and t=150 minutes), coronary perfusate 
samples were collected. Purines, a sensitive indicator of myocardial ischemia, were deter-
mined by high-performance liquid chromatography (HPLC) as previously described(20;21). 
The total amount of purines released during ischemia and reperfusion, corrected for coro-
nary flow and left ventricular weight, was calculated (area under the curve).
RT-PCR 
Snap-frozen LV tissues were used to extract total RNA. Total RNA was isolated using the 
method of acid guanidium thiocyanate lysis (22). RNA was quantified using a GeneQuant II 
(Pharmacia Biotechnology). First strand cDNA was synthesized from 1 μg RNA using the RT-
PCR Core kit (Perkin-Elmer). Reverse transcriptase (RT) PCR for EPO-R was performed using 
a forward (5’- AGGACACCTACCTGGTATTGGA-3’) and reverse primer (5’-CAGGCCCAGAGA-Chapter 5 66
GGTTCTCA-3’), yielding a product of 73 bp. To determine the specificity of the PCR reaction 
the amplicon was digested with Nci I to obtain the expected 39 bp and 34 bp fragments. 
Western blotting
Snap frozen LV tissues were homogenized in Radio-Immuno-Precipitation-Assay (RIPA) buf-
fer (1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 10 mM 
-mercaptoethanol, 10 mg/ml PMSF, 5 μl/ml aprotinin, 100 mM sodium orthovanadate, 5 
μl/ml benzamidine, 5 μl/ml pepstatine A, 5 μl/ml leupeptine in 1× PBS). Protein concen-
trations were determined using the DC assay (Bio-Rad) with a bovine albumin standard. 
Protein levels of EPO-R, phosphorylated MAP kinases p42/p44 and phosphorylated STAT5 
were determined by Western blot. Protein samples (50 μg) were separated by sodium do-
decyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and transferred to nitrocel-
lulose membranes, followed by staining with Ponceau S solution (Sigma). Membranes were 
incubated with primary antibody against phosphorylated MAP kinases p42/p44 (1:1000 
dilution, New England Biolabs), phosphorylated STAT5 (1:1000 dilution, Upstate biotech) 
and EPO-R (1:250 dilution; C-20 and M-20, Santa Cruz Biotechnology). Horseradish per-
oxidase-conjugated anti-mouse or anti-rabbit IgG (1:2000, Santa Cruz Biotechnology) was 
used as secondary antibody. Signals were detected by the ECL-detection method (Amersham) 
and quantified by densitometry. 
ImmunIohistochemistry
For immunohistochemistry, cryosections (4 μm) from a midpapillary slice of the left ventricle 
were fixed in acetone. Hereafter, sections were incubated with two different polyclonal anti-
EPO-R antibodies (1:50) (M-20, C-20; Santa Cruz). A two-step indirect peroxidase detection 
system was employed to visualize the expression pattern of the EPO-R. Sections of placenta 
and breast carcinoma were used as a positive control(23;24). Slides omitting the primary 
antibody and preincubation with blocking peptide (10:1) were used as negative controls. 
For apoptosis detection, sections were incubated with an antibody that specifically recognizes 
the active form of caspase-3 (1:50; New England Biolabs), as previously reported(25). For 
quantitative analysis, active caspase-3 positive cells in thirty random fields per section (80-
120 cells per field) were counted at high-power magnification. Tissue sections of colonic 
adenocarcinoma served as a positive control(26;27).
Statistical Analysis
Values shown are mean ± SEM. We used a linear regression model with repeated measures to 
compare the functional responses to EPO treatment. Data regarding the purine overflow and 
caspase-3 immunohistochemistry were analyzed by Student’s t-test. Statistical significance 
was defined as p<0.05.Erythropoietin induces ex-vivo cardioprotection 67
Results
Expression pattern and functionality of EPO-R in heart
We determined the expression of EPO-R in normal cardiac tissue by immunohistochemis-
try. Immunostaining for EPO-R was predominantly observed in interstitial cells, including 
endothelial cells and fibroblasts. Cardiomyocytes showed weak expression of the EPO-R (Fig 
1a). We found similar expression patterns with both antibodies, while incubation with 10x 
excess of blocking peptide completely abolished the signal (data not shown). Western blot-
ting revealed a specific signal for the EPO-R with both antibodies at the expected size of 100 
kDa (Fig 1b). Further, we studied the expression levels of the EPO-R after ischemia-reperfu-
sion injury. In the group without EPO perfusion, we did not observe a change in the expres-
sion level of the EPO-R compared to non-ischemic tissue. However, EPO treatment  during 
ischemia-reperfusion induced a 26 ± 8.3%  downregulation of the EPO-R. Further, RT-PCR 
revealed EPO-R gene transcription in the rat heart. Specificity of the product was confirmed 
by restriction fragment length analysis (Fig 1c). We further explored potential signal trans-
duction pathways of the EPO-R, by infusing 10 U/ml EPO in Langendorff-perfused hearts 
for twenty minutes. This resulted in a 50% increase in levels of phosphorylated MAP kinase 
p42/44 in the left ventricles of EPO-perfused hearts compared with vehicle perfused hearts 
(Fig 1d). No increase in the levels of phosphorylated STAT5 were detected.
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Figure 1a, Immunostaining for EPO-R in normal cardiac tissue. Staining is predominantly observed in interstitial cells, 
including endothelial cells and fibroblasts. Weak staining is observed in cardiomyocytes.1b, Western blot analysis of 
EPO-R expression in non-ischemic tissue with two different antibodies (M-20, C-20). 1c, RT-PCR analysis of EPO-R 
mRNA transcripts (73 bp), after partial digestion with restriction enzyme Nci I, two specific products (39 bp  and 34 
bp) are obtained. 1d, Effects of EPO (10 U/ml) on phosphorylated STAT5 (92 kDa) and MAP kinase p42/p44 (42 and 44 
kDa), assessed by Western blot analysis (n=6).Chapter 5 68
Effects of EPO on Cardiac Function
To test the potential protective effects of EPO in the heart, we performed low-flow ischemia/
reperfusion experiments in isolated rat hearts. Baseline characteristics, body weight, heart 
weight, CF and LVP did not differ between both groups (data not shown). During low-flow 
ischemia the cardiac function decreased to a similar extent in the two groups, irrespective of 
EPO treatment.  During reperfusion, post-ischemic hyperemia occurred in both groups, but 
CF was restored to a significantly higher level during the two hours reperfusion period in the 
EPO treated group (p=0.02, Fig 2a).  Furthermore, LVP was significantly increased through-
out the reperfusion period in the EPO treated group compared with the vehicle treated group 
(p=0.01, Fig 2b). 
Effects of EPO on Cellular Damage
To determine the effect of EPO perfusion on cellular damage, we measured purine overflow 
at different time points during stabilization, ischemia and reperfusion period. Total overflow 
of purines during reperfusion showed a 56% decrease (711 ± 183 nmol/g versus 1614 ± 
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317 nmol/g) (p<0.05) in the EPO treated group, compared with the vehicle treated hearts. 
A smaller difference was observed during the ischemic period between the EPO perfused 
hearts and the control group, 660 ± 53 nmol/g versus 898 ± 200 nmol/g, respectively 
(p=NS; Fig 3). No purines were detected at baseline. 
Furthermore, we studied the anti-apoptotic effects of EPO perfusion on the heart. Staining 
with anti-active caspase-3 was mostly restricted to endothelial cells and fibroblasts (Fig 4a). 
The hearts perfused with EPO demonstrated a 15% reduction in apoptotic cells (2.1% ± 0.12 
versus 1.8% ± 0.09) (p<0.05, Fig 4b). 
Discussion
In the present study, we demonstrated the presence of a functional EPO-R in adult cardiac 
tissue and we showed that EPO administration limited cardiac damage and preserved cardiac 
function after ischemia/reperfusion injury. However, the mechanism by which EPO pre-
serves cardiac function is currently unknown. 
We found that EPO stimulation increases the levels of phosphorylated MAP kinases p42/p44 
in normal rat heart. This pathway has already been implicated as a survival pathway in car-
diac cells after ischemia/reperfusion injury, by inhibiting apoptosis (28-30). A study by Yue 
et al. provided more evidence for the role of MAP kinases in ischemia-reperfusion injury by 
demonstrating that inhibition of the MAP kinases p42/p44 pathway exacerbated cardiac in-
jury and showed a diminished functional recovery compared with control hearts(31). Thus, 
activation of this pathway seems to be important for survival of cardiac cells by protecting 
them from programmed cell death. With respect to STAT5, we did not observe difference in 
the amount of phosphorylated STAT5 after EPO perfusion for twenty minutes. This might be 
related to different time-points of STAT5 phosphorylation after perfusion with EPO. Further-
more, this pathway could play a minor role in the cardiac EPO signaling, as shown in vascular 
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Figure 3. Effect of EPO perfusion on total purine overflow during ischemia and reperfusion (area under the curve). 
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smooth muscle cells by Ammarguellat et al (11;32). Future experiments will be needed to 
precisely explore the EPO signaling pathways in the heart.
Both ischemic and reperfused myocardium can undergo apoptosis, however, during reperfu-
sion, accelerated apoptosis occurs in cardiac cells(33). We observed that EPO limits cardiac 
damage by 56% during reperfusion. A recent paper from Scarabelli et al showed that in the 
early stages of reperfusion, apoptosis is first seen in endothelial cells and is spreading to sur-
rounding cardiac myocytes, suggesting that reperfusion induces the release of pro-apoptotic 
mediators from endothelial cells(34). We found that the EPO-R was predominantly localized 
to endothelial cells and fibroblasts. Interestingly, we observed in these cells a reduction of 
apoptosis of 15%, when the hearts were perfused with EPO. By preventing apoptosis in these 
cells, it is tempting to speculate that EPO can preserve vascular flow and ultimately protect 
the myocardium. Although a reduction of 15% in apoptotic cells seems modest, recent in-
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Figure 4. Immunostaining for active caspase-3 in ischemic cardiac tissue without EPO treatment. 4B. Percentage 
of active caspase-3 positive cells at the end of reperfusion in isolated rat hearts perfused with or without EPO and 
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vestigations suggests that apoptosis after myocardial infarction is progressive, and therefore 
small amounts of apoptotic cells may result in more extensive cell loss(35).  Recent data 
reported on the beneficial effects of preconditioning in the rodent heart in which exposure 
of wild-type mice to intermittent hypoxia resulted in protection from ischemia-reperfusion 
injury(36). Ischemic preconditioning was absent in mice heterozygous for a knockout in 
the HIF-1α gene. Further, in wild-type mice, EPO administration at 24 hours prior to ex vivo 
ischemia-reperfusion resulted in a reduction in apoptosis and an increased cardiac recovery. 
While these findings are in accordance with our results the present study suggests that there 
is no need for an extended period of pretreatment for EPO to exert its protective effects.
In addition to its anti-apoptotic effects, EPO may protect the myocardium through other 
mechanisms that have not been assessed in this work. Oxidative stress plays an import role 
in the reperfusion damage observed in the myocardium(37). Recent research suggests that 
EPO can also directly protect tissue against the effects of free radicals(38). Furthermore, it 
has been shown that EPO may increase the Nitric Oxide (NO) production when EPO-in-
duced erythrocytosis occurs, reviewed by Smith et al.(39). Transgenic mice overexpressing 
human erythropoietin showed higher NO synthase levels and an increased NO-mediated 
endothelium derived relaxation(40). On the other hand, Noguchi et al showed that one-
week of erythropoietin treatment in rabbits, resulted in a decreased response to endothelium 
dependent vasodilators(41). EPO has also been shown to act as a cardioprotective agent, by 
modulating the cardiac Na+-K+-pump(42). 
EPO has been widely used in clinical practice for more than a decade. A recent study of Sil-
verberg et al. showed the beneficial effects of rh-EPO therapy in CHF patients(14). They con-
ducted a placebo controlled study in 32 mild anemic patients with severe CHF (NYHA ≥III) 
and treated them with rh-EPO. Over a mean of 8.2 +/- 2.6 months, left ventricular ejection 
fraction increased 5.5% in the treatment group, compared to a decrease of 5.4% in the con-
trol group. These results strongly suggest an important role for rh-EPO in patients with CHF. 
Although correction of anemia has beneficial effects on cardiac function, non-erythropoietic 
effects are also likely to play a role. More evidence for non-erythropoietic effects of EPO in 
human was provided by Ehrenreich et al (43). They recently conducted a pilot double blind 
randomized clinical trial to investigate the acute effects of EPO treatment in patients with 
ischemic stroke. Administration of EPO within 8 hrs after stroke reduced brain infarct size 
and improved the clinical outcome. As there are many similarities between brain and heart 
ischemia, EPO administration may become an adjunctive therapy for the treatment of acute 
coronary syndromes. Further work is needed to determine the mechanisms by which EPO 
reduces cardiac damage and preserves cardiac function.
In conclusion, this study suggests that EPO treatment is effective in reducing myocardial 
damage and preserving cardiac function after ischemia/reperfusion injury. This implies an 
organ protective role of EPO beyond erythropoiesis and warrants the search for organ spe-
cific EPO analogues.Chapter 5 72
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Abstract
Objectives:  We assessed the effects of erythropoietin (EPO) treatment in a rat model of post-MI 
heart failure.
Background:  EPO, traditionally known as a hematopoietic hormone, has been linked to neovas-
cularization. Whereas administration of EPO acutely after myocardial infarction (MI) reduces 
infarct size and improves cardiac function, its role in the failing heart is unknown. 
Methods:  Rats underwent coronary ligation or sham surgery. Rats with MI were randomly 
assigned to: untreated (MI), a single bolus of EPO immediately after MI induction (MI-EPO-
early), EPO treatment immediately after MI and once every three weeks (MI-EPO-early+late) 
and EPO treatment starting three weeks after induction of MI, once every three weeks (MI-
EPO-late). After nine weeks, hemodynamics, infarct size, myosin heavy chain (MHC) iso-
forms, myocyte hypertrophy and capillary density were measured. 
Results:  EPO treatment started immediately after MI (MI-EPO-early and MI-EPO-early+late) 
resulted in a 23-30% reduction in infarct size (p<0.01), and accordingly hemodynamic im-
provement. EPO treatment, started three weeks after MI (MI-EPO-late), did not affect infarct 
size, but resulted in an improved cardiac performance, reflected by a 34% reduction in left 
ventricular end-diastolic pressure (p<0.01), and 46% decrease in ANP levels (p<0.05). The 
improved cardiac function was accompanied by an increased capillary density (p<0.01), an 
increased capillary-to-myocyte ratio (p<0.05) and a partial reversal of β-MHC (p<0.05) in 
all treated groups. 
Conclusion:  In addition to its effect on infarct size reduction, EPO treatment improves cardiac 
function in a rat model of post-MI heart failure. This observation may be explained by neo-
vascularization, associated with an increased α-MHC expression.
Introduction
Erythropoietin (EPO) is best known as a hematopoietic growth factor, promoting prolifera-
tion and differentiation of erythroid progenitor cells. However, the expression of the EPO-
receptor outside the hematopoietic system, including endothelial cells, cardiomyocytes and 
neurons, may suggest additional effects of EPO beyond hematopoiesis(1-4). 
Since an insufficient amount of capillaries may lead to left ventricular dilatation and heart fail-
ure after myocardial infarction (MI) (5), treatment directed towards increasing capillary den-
sity might be beneficial in heart failure. Expanding evidence shows that EPO is involved in an-
giogenesis. It has been shown that stimulation of cultured endothelial cells with EPO resulted 
in cell proliferation, chemotaxis and differentiation into vascular structures(6). Furthermore, 
Jaquet et al found that EPO and Vascular Endothelial Growth Factor (VEGF) were equally effec-
tive in stimulating angiogenesis in endothelial cells derived from the myocardium(7). Most 
recently, it has been shown that EPO treatment in a rat stroke model, resulted in an increased 
capillary density around the ischemic lesion(8). In addition, EPO has been implicated to play 
a protective role during acute ischemia in brain (2;9;10) and heart(11-13). 
Pretreatment with exogenous EPO rescued hypoxic cultured cardiomyocytes from apopto-
sis(12). EPO perfusion during ex-vivo ischemia-reperfusion, improved left ventricular func-
tion and reduced cellular damage(4;13;14). Acute, systemic treatment with EPO, in a rodent 
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apoptosis(12), even when EPO was administered after reperfusion(11;15). 
While the cardioprotective effects of EPO during acute MI are increasingly recognized, the 
role of EPO treatment in chronic heart failure (CHF) is unknown. Therefore, we assessed the 
effects of EPO treatment in a rat model of post-MI heart failure(16). In this model induction 
of MI leads to a time and infarct size related ventricular dilatation and heart failure(17). We 
hypothesized that EPO treatment initiated after heart failure development (three weeks after 
induction of MI) would improve cardiac performance, possibly by increasing capillary den-
sity. To distinguish the acute effects of EPO (i.e. infarct size reduction) from its effects in CHF, 
we studied two additional groups. In one group we administered only a single dose of EPO 
immediately after MI, and in a second group we administered EPO immediately after MI and 
continued EPO treatment during the experiment. 
Methods
Animals
We used male Sprague Dawley rats weighing 270-330 g (Harlan, Zeist, The Netherlands). 
Animals were fed ad libitum, and housed in groups of four to five rats, according to institu-
tional rules with 12:12 hours light-dark cycles. The experimental protocol was approved by 
the Animal Ethical Committee of the University of Groningen. 
Design of the study
Rats were either subjected to left coronary artery ligation (n=85) or sham surgery (n=8). 
Rats with MI were randomized to one of four groups; untreated (MI) or three different treat-
ment strategies with EPO: a single bolus of EPO immediately after ligation (MI-EPO-early), 
EPO treatment directly after ligation and once every three weeks (MI-EPO-early+late) and 
EPO treatment starting three weeks after ligation, once every three weeks (MI-EPO-late). 
EPO (Darbopoetin-alpha; Aranesp) was administered intraperitoneally at a dose of 40 μg/kg, 
which equals 8.000 U/kg recombinant human EPO (Amgen Inc., Thousands Oaks, CA, USA) 
and is in close range of known dosages for organ protection(11;12;18). Hematocrit was 
measured at baseline and at week one, three, four, six and nine after surgery. Persons blinded 
to the treatment groups performed the analysis of samples obtained from the experiments.
Myocardial infarction model
This model has been described previously(16). Briefly, rats were anesthetized with 2% iso-
flurane in 2.5L oxygen/minute. After intubation, the rats were put on a mechanical ventilator 
(frequency 90/min) and a left-side thoracotomy was performed. MI was induced by ligating 
the proximal portion of the left coronary artery, beneath the left atrial appendage. In sham 
operated rats, the same surgery was performed, without ligating the suture. 
Hemodynamic measurements
After nine weeks rats were anaesthetized as described above. Microtip pressure transducer 
(Millar Instr. Inc.) was inserted into the left ventricular cavity via the right carotid artery. Af-
ter a 3-min period of stabilization, heart rate (HR), left ventricular systolic pressure (LVSP), 
left  ventricular  end-diastolic  pressure  (LVEDP),  and  developed  left  ventricular  pressure 
(dLVP=LVSP-LVEDP) were measured. As indices of contractility and relaxation, the maximal Chapter 6 80
rates of increase and decrease in LVP (+dP/dtmax and -dP/dtmax) were determined. The catheter 
was retracted into the aortic arch and arterial systolic and diastolic blood pressures (SBP, 
DBP) were recorded. 
Plasma N-terminal ANP levels 
Arterial blood was collected after nine weeks, anti-coagulated with EDTA, and plasma was 
stored at –80˚C until assayed. Plasma N-terminal atrial natriuretic peptide (N-ANP) was mea-
sured by a commercially available radioimmuno-assay (Biotop, Oulu, Finland), as described 
previously(19).
Infarct size and left ventricular hypertrophy
After hemodynamic measurements, hearts were rapidly excised and weighed. Mid-papillary 
slices were prepared for immunohistochemistry. Slices were fixed in 4% paraformaldehyde 
and paraffin-embedded. Infarct size was determined by planimetry at mid-ventricular levels 
in transverse slices on picrosirius red/fast green–stained sections. Infarct size was expressed 
as the percentage of scar length to total left ventricular circumference, as described previ-
ously(20;21). Deparaffinized 5-μm thick sections were stained with a Gomori’s silver stain-
ing, in order to visualize individual myocytes in the viable LV wall, the area with the most 
pronounced underperfusion(22). Using image analysis (Zeiss KS 400, Germany), concentric 
myocyte hypertrophy in the viable LV wall, remote from the infarcted area, was measured as 
Table 1.   Characteristics of the experimental groups 
Sham MI MI-EPO-early MI-EPO-late MI-EPO-early+late
General
n       8           12        12     13     13
Infarct size (% of LV)       …     43±3       30±2§     41±3     33±2§
Hemodynamics
Heart rate (bpm) 313±8 324±6 332±7  326±7 328±8
SBP (mmHg) 127±3      111±4†     115±3†    120±3‡    122±3‡
DBP (mmHg)    78±2     78±2     79±2      83±3   86±2
Body/organ weight
BW (g)   390±10   395±11 401±8 400±7   421±6
Lungweight/BW (mg/g)       3.9±0.1            6.4±1.0†    4.2±0.5§     3.9±0.1§    3.9±0.2§
Heartweight/BW (mg/g)      3.2±0.1            4.0±0.2†    3.8±0.1†            3.7±0.1*      3.7±0.1*
Hematocrit
baseline (%)    48±0.6     47±0.3      48±0.5         48±0.6      47±0.6
1 week (%)   48±0.6           47±1.1     58±0.9†,§         46±0.7         59±0.7†,§
3 weeks (%)      50±1.1            49±0.7     53±0.5†,§         49±0.7         53±0.7†,§
4 weeks (%)         50±0.5       51±0.8    50±0.4       62±0.5†,§        64±1.8†,§
6 weeks (%)         50±0.4    50±0.7    49±0.6      60±0.7†,§         61±0.7†,§
9 weeks (%)         44±0.5           44±1.5     44±0.7      54±1.3†,§         56±1.7†,§
Data are presented as mean±SEM. n indicates number of animals; LV, Left Ventricle; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; BW, bodyweight. *p<0.05; †p<0.01 vs Sham; ‡p<0.05, §p<0.01 vs. MI.Erythropoietin attenuates heart failure 81
the cross-sectional area of transversally cut myocytes showing a nucleus. Myocyte density was 
calculated as the average number of myocytes per tissue area. In each stained section, mea-
surements were averaged from three different counting fields (± 75 myocytes per heart)
Myosin Heavy Chain (MHC) Isoform Analysis
Samples of the left ventricle (not infarct area), were frozen in liquid nitrogen and stored at 
–80˚C. The freeze dried samples were dissolved in a buffer and gel electrophoresis was per-
formed as described previously(23). Samples (0.5μg) were run at constant current (24 mA) 
for 5 hours. Silver staining of the gels and laser scanning densitometry was performed to 
identify differences in myosin isoform composition (i.e.α-MHC and β-MHC).
Capillary density
To visualize capillaries in the myocardium in the same area as used for the measurements 
of the myocyte size, endothelial cells were stained with biotin-labeled Lectin GSL (1:100; 
Sigma-Aldrich), as previously described (16). Since Lectins stain not only capillaries but also 
other vessels, a size criterion of 10 μm was used to exclude small arterioles and venules. Im-
age analysis (Image Pro-plus version 4.5) was used to measure capillary density; calculated 
as the number of capillaries per tissue area. The measured total tissue area was corrected for 
the remaining interstitial space. Actual neovascularization was derived from an increased 
capillary to myocyte ratio, which has been calculated as capillary density divided by myocyte 
density(24). 
Statistical analysis
Data are presented as mean±SEM. Statistical analysis between groups was performed by 1-
way ANOVA. When a statistically significant difference was detected, a Fisher’s protected LSD 
post-hoc analysis was performed. Correlation analysis was performed with Pearson’s correla-
tion tests. Differences were considered significant at p<0.05.
Results
General
Overall mortality following MI was 41%. Mortality occurred only in the first 24 hours after 
induction of MI. There were no statistically significant differences in mortality between the 
four groups (MI:50%, MI-EPO-early:40%, MI-EPO-late 32% and MI-EPO-early+late:41%; 
p=0.54). No mortality was observed in sham-operated rats. At baseline, no differences in 
body weight were observed (data not shown). General characteristics after nine weeks are 
shown in table 1. Body weight was comparable among the five groups. Among groups with 
MI, systolic blood pressure (SBP) was significantly lower only in MI and MI-EPO-early com-
pared to sham; p<0.01. SBP was significantly higher in MI-EPO-late and MI-EPO-early+late, 
compared to MI group (p<0.05). No significant differences were observed in heart rate and 
diastolic blood pressure (DBP), although there was a trend towards higher DBP in the groups 
repeatedly treated with EPO (MI-EPO-late and MI-EPO-early+late). The changes of the he-
matocrit throughout the experiment are also shown in table 1. After nine weeks hematocrit 
values were significantly elevated in the MI-EPO-late and MI-EPO-early+late, compared to 
other groups.Chapter 6 82
Infarct size 
LV-infarct size (% of LV) was comparable between MI and MI-EPO-late, 43% and 41% re-
spectively (p=0.60; table 1). Treatment with EPO immediately after coronary artery ligation, 
reduced infarct size by 30% in MI-EPO-early and by 23% in MI-EPO-early+late group (both 
p<0.01 vs. MI; table 1). 
Hemodynamic measurements
Hemodynamic data obtained nine weeks after surgery are summarized in figure 1. LVSP and 
developed LVP (dLVP) were both clearly diminished in MI compared to sham operated rats 
(p<0.01 for both). MI-EPO-late and MI-EPO-early+late showed a significantly higher LVSP 
and dLVP, compared to MI (both p<0.05). One single bolus of EPO immediately after ligation 
(MI-EPO-early) did not result in a significantly improved LVSP or dLVP (figure 1A and 1B).
LVEDP was elevated in MI compared to sham operated rats (21±3mmHg vs. 8±1mmHg; 
p<0.01). Importantly, EPO treatment started three weeks after MI (MI-EPO-late), resulted in 
a 34% decrease in LVEDP, compared to MI (p<0.01), despite similar infarct sizes. Immediate 
treatment with EPO after induction of MI (MI-EPO-early and MI-EPO-early+late) led to a 
27% and 38% reduction in LVEDP respectively, compared to MI group (p<0.05 and p<0.01; 
figure 1C). 
Myocardial contractility (+dP/dtmax) and myocardial relaxation (-dP/dtmax) were both impaired 
in MI compared to the sham group (both p<0.01). MI-EPO-late and MI-EPO-early+late showed 
an improved contractility and relaxation compared to MI (all p<0.05). In contrast, when only 
one single bolus of EPO was administered immediately after MI (MI-EPO-early), contractility 
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Figure 1. Effects of myocardial infarction and EPO treatment on hemodynamic parameters. LVSP indicates left ven-
tricular systolic pressure; dLVP, developed left ventricular pressure; LVEDP, left ventricular end diastolic pressure; 
+dP/dtmax and -dP/dtmax, maximal rate of increase and decrease of ventricular pressure, respectively. * p<0.05 vs. MI, 
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and relaxation were not significantly improved compared to MI (figure 1D and 1E).
N-terminal ANP levels
Figure 2 shows that plasma N-ANP levels were three-fold increased in MI group (p<0.01 
vs. sham-operated animals). Furthermore, N-ANP levels were significantly reduced in the 
MI-EPO-late and MI-EPO-early+late groups (both p<0.05 vs. MI), returning to sham values 
(both p=NS vs. sham). The MI-EPO-early group showed a trend towards lower N-ANP levels 
(p=0.07 vs. MI).
Organ weights and LV hypertrophy
As shown in table 1, the ratios of heart weight (HW) to body weight and that of lung weight 
to body weight were significantly increased in the MI compared to the sham-operated group 
(both p<0.01). Lung weight to body weight (an indirect expression of the LV-end diastolic 
pressure and thus severity of heart failure) was significantly reduced in all EPO treatment 
groups (all p<0.01 vs. MI). A trend towards lower HW to body weight compared to MI was 
observed in MI-EPO-late and MI-EPO-early+late groups. LV hypertrophy was further studied 
by histological analysis. Representative photomicrographs of Gomori stained stections of the 
viable LV free wall are shown in figure 3A. MI resulted in a 35% increase in myocyte cross-
sectional area, compared to sham (p<0.05). All EPO treated groups showed a trend towards 
a smaller myocyte cross-sectional area, although this did not reach statistical significance 
(figure 3B).
Differences in MHC isoform composition
Relative proportion of cardiac α-MHC and β-MHC were compared in LV protein samples 
between the five different groups. MI resulted in a more than 5-fold increase in expression 
of β-MHC, compared to sham operated rats (p<0.01). EPO treatment in all three groups 
reduced the expression of β-MHC by 26-31%, compared to MI (p<0.05, figure 4).
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Figure 2. Plasma N-terminal ANP levels. * p<0.05 vs. MI, ** p<0.01 vs. MI, # p<0.01 vs. Sham.Chapter 6 84
Capillary density
Capillaries stained with lectin were clearly discernable in the myocardium. Figure 5A shows 
representative photomicrographs of the five different groups. Capillary density was signifi-
cantly reduced in the MI group compared to the sham-group (p<0.01). EPO treatment in all 
three groups prevented the decrease in capillary density after induction of MI and restored 
it to sham values, as shown in Figure 5B (p=NS vs. sham). Furthermore, in the MI-EPO-late 
and MI-EPO-early+late groups, we observed a 39% and 48% increase in capillary to myo-
cyte ratio, respectively (both p<0.05 vs. MI), whereas MI-EPO-early showed a clear trend 
(p=0.05 vs. MI) towards an increased capillary to myocyte ratio (figure 5C). 
In order to relate LV functional parameters through a MHC-shift to increased capillarization, 
correlations were determined. We observed a strong correlation between capillary density 
and β-MHC expression (r=-0.47, p<0.01) and subsequently between β-MHC expression 
and cardiac contractility and relaxation, r=-0.52 and r=0.61 respectively (both p<0.01). 
Furthermore capillary density was correlated with myocardial contractility (r=0.32) and 
relaxation (r=-0.37; both p<0.05).  
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Discussion
In the present study, the effects of EPO treatment in a rat model of post-MI heart failure were 
examined. To our knowledge, this study shows for the first time that EPO treatment initiated 
three weeks after induction of MI results in an improved cardiac function, as shown by a 17% 
increase of dLVP at 34% reduction in LVEDP and a 46% decrease in N-ANP levels. Further-
more, our data indicate that EPO restores capillary density to sham levels and increases the 
capillary to myocyte ratio, indicating neovascularization. 
Myocardial structure and cardiac function
Previous studies already revealed that EPO has ancillary properties besides hematopoiesis. 
One of the first studies on EPO in the heart showed that EPO injected intraperitoneally 
for seven days, reduced cardiomyocyte loss by 50% after ischemia-reperfusion injury(25). 
These observations have been confirmed by others. Parsa et al. showed a 25% reduction in 
infarct size after 4 days of permanent occlusion of the left circumflex coronary artery in 
rabbits(12). A single dose of EPO at the onset of MI reduced infarct size, which was accom-
panied by reductions in LV size and an improved LV ejection fraction, measured by echocar-
diography, during eight weeks follow-up(26). Our results are in line with these findings; one 
single dose of EPO administered immediately after induction of MI, reduces infarct size by 
30% and improves hemodynamics. Mechanisms behind this acute protective effect of EPO 
may be related to its anti-apoptotic effect. We and others showed that in the acute phase of 
MI, EPO markedly prevents cardiac cells from undergoing programmed cell death (apopto-
sis)(11;12;15;25). After MI, apoptosis is first observed in endothelial cells from small coro-
nary vessels, spreading to the surrounding cardiomyocytes(27). Since the EPO-receptor is 
predominantly expressed on endothelial cells, preventing apoptosis in these cells may rescue 
the underlying myocardium(13). Recently, it has been postulated that cardiac fibroblasts may 
also play a role in the cardioprotective effects of EPO(15). 
Although a single dose of EPO clearly improves cardiac performance, prolonged EPO treat-
ment (MI-EPO-early+late) was associated with a further restoration of cardiac function. 
Mechanisms involved in this process are most likely distinct from its acute cardioprotective 
effect. This is clearly demonstrated by the finding that EPO treatment, initiated three weeks 
after MI, although not reducing infarct size, significantly improves cardiac function, reflected 
by a 17% increase of dLVP at 34% decrease in LVEDP, and restoring N -ANP levels to sham 
values. Since the effect of EPO treatment in this group could not be explained by infarct size 
reduction, other properties of EPO should be considered to elucidate the observed beneficial 
effects of EPO in heart failure. 
Neovascularization
EPO has been shown to possess proangiogenic properties. As discussed above, the EPO-re-
ceptor is expressed on endothelial cells and EPO has been shown to stimulate the prolif-
eration and migration of endothelial cells in vitro(6). Additional experiments in chick em-
bryos demonstrated that EPO treatment results in angiogenesis similar to other well-known 
angiogenic cytokines(6). Furthermore, EPO induces vascular sprouting in a rat aortic ring 
model(28). In human cultured myocardial tissue, EPO stimulates capillary outgrowth com-
parable to VEGF(7). In a rodent model of hind-limb ischemia, EPO increases capillary density 
1.6-fold(29). In a rat model of chronic renal failure, characterized by left ventricular hyper-Erythropoietin attenuates heart failure 87
trophy and capillary deficiency, EPO treatment results only in a small non-significant increase 
in cardiac capillary density(30). In a rat model of stroke, EPO treatment, initiated 24 hours 
after infarction, enhances angiogenesis and improves neurological function, while it does 
not significantly influence infarct size. Our results suggest a similar effect of EPO in the heart. 
We find that EPO treatment restores capillary density to sham values and increases capillary 
to myocyte ratio, indicating actual capillary growth(24), which is more pronounced in the 
groups with prolonged EPO treatment. 
To study the functional consequences of increased capillarization, we examined the expres-
sion of different MHC isoforms in heart tissue. Cardiomyocytes express both fast α-MHC 
and slow β-MHC isoforms, which differ on the basis of ATPase activity. Recently, it has been 
shown that expression of a small amount of α-MHC (~12%) in rat cardiomyocytes signifi-
cantly increases power output, indicating that a small shift in MHC composition as we found 
in all EPO treated groups may improve contractility(31). Increased capillary density was 
significantly correlated with the percentage of β-MHC isoform as well as with myocardial 
function (+dP/dtmax and -dP/dtmax), providing a link between neovascularization and func-
tional effects of EPO.
The mechanism behind the effect of EPO on new blood vessel formation in the heart remains 
unknown. In general, stimulation of in situ endothelial cell proliferation or bone-marrow 
derived endothelial progenitor cells (EPCs) might play a role. Previous work showed that EPO 
effectively increases the amount of circulating EPCs(32), and significantly induces angio-
genesis(29). Future experiments are needed to delineate the mechanism of EPO stimulated 
capillary growth.    
Hematopoietic effect
Another important property of EPO that might be involved in the cardioprotective effect ob-
served in our study, is its hematopoietic effect. Human recombinant erythropoietin increases 
the number of reticulocytes after administration to rats after 3-4 days with maximum after 8-
11 days(33). In our study we observed significant hematocrit elevation one-week after a single 
dose of EPO. In the groups treated with multiple EPO doses, hematocrit remained significantly 
elevated throughout the experiment. The beneficial effects seen in these groups might thus, 
in part, be explained on the basis of increased oxygen-carrying capacity of blood. However, 
the effects of higher red blood cell mass on oxygen delivery is not straightforward, since 
elevated hematocrit may downregulate NO synthesis and thus impairs tissue blood flow(34). 
In the clinical setting, increasing the number of red blood cell mass by blood transfusion has 
been reported to improve outcome in elderly patients after acute MI(35). Nevertheless, this 
beneficial effect is only seen in patients with hematocrit <33%. On the other hand, reduc-
tion in the infarct size observed in the early treated groups, could not be attributed to the 
hematopoietic effect of EPO, since cell death and MI expansion occur mainly during the first 
3 days after ischemic insult(26) and thus before significant hematocrit elevation.
Conversely, an increase in hematocrit may itself tend to deteriorate myocardial perfusion 
through adverse rheological effects. Elevated hematocrit levels (up to 80%) in polyglobulic 
mice, overexpressing EPO, enlarge cerebral infarct volumes and leukocyte infiltration after 
permanent occlusion of middle cerebral artery(36). Furthermore, EPO administration and 
consequent higher hematocrit has been associated with other adverse cardiovascular effects. 
Therapeutic levels of EPO may cause higher incidence of thrombosis (37) and could lead to 
blood pressure elevation(38). In the present study, rats repeatedly treated with EPO, show a Chapter 6 88
higher systolic blood pressure. This increase might be related to the improved cardiac func-
tion; however, the systolic blood pressure remained below the values observed in the sham 
operated group.
Clinical Implications
In clinical settings, EPO treatment has already been used to correct anemia in patients with 
CHF. Anemia is frequently observed in patients with CHF and related to increased morbid-
ity and mortality(39;40). Furthermore, not only anemia, but also elevated endogenous EPO 
levels are independently associated with an impaired outcome in CHF(41). Normalization 
of hemoglobin levels in mild anemic patients with CHF has a positive effect on LV ejection 
fraction(42) and peak VO2(43). In addition to correction of anemia, other non-hematopoi-
etic effects of EPO may play a role in the improvement observed in patients with CHF treated 
with EPO. 
Besides the treatment of anemia, EPO is currently under investigation for its neuroprotective 
properties. In the first clinical, randomized, proof-of concept trial, EPO was given to patients 
with ischemic stroke (44). EPO administration in high-doses (entire dose 100.000 IU/ 
given in three days) proved to be both safe and beneficial. Patients randomized to the EPO 
group showed significant improvement in clinical outcome parameters and a trend towards 
smaller infarct sizes. 
However, chronic therapy with EPO is also associated with adverse effects related to hemat-
ocrit elevation, such as hypertension and tromboembolic complications. This could be over-
come by using a lower dose of EPO, as shown by Bahlmann et al(45). In this study, low-dose 
of darbepoetin (0.1 μg/kg/week) rendered tissue protection in the kidneys even without 
raising hematocrit levels. The recently discovered non-hematopoietic derivates of EPO re-
taining tissue protection but without the undesired effects on hematopoiesis, may become 
another possibility for chronic administration (46).
Limitations
Several limitations of the present study have to be acknowledged. Although a clear increase 
in capillary density and capillary to myocyte ratio was observed, the improvement of cardiac 
function might also be related to other effects of EPO treatment. Since we did not perform 
sequential measurements of cardiac function, further studies would be needed to specifically 
denote the time-dependent effect of EPO treatment on attenuation of heart failure develop-
ment. 
We did not measure the direct myocardial perfusion and therefore, functional evidence of 
an improved perfusion remains unclear. However, we observed a clear correlation between 
capillary density and β-MHC expression and cardiac function. Furthermore, we used the 
Fisher’s LSD post-hoc statistical test for analyzing our data, which does not control for mul-
tiple comparisons.   
Conclusion
In summary, the present study demonstrates that EPO treatment in a rat model of heart fail-
ure improves cardiac function beyond its effect on infarct size reduction. This improvement 
could be explained by the increased capillary density and capillary to myocyte ratio, indicat-
ing formation of new blood vessels.Erythropoietin attenuates heart failure 89
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Abstract
Background: The hematopoietic hormone erythropoietin (EPO) is involved in postnatal neo-
vascularization and was shown to enhance endothelial progenitor cells (EPCs) mobilization 
from bone marrow. We hypothesized that low-dose EPO treatment, not leading to hematocrit 
increase, would mobilize EPCs, increase capillarization and preserve cardiac function in a 
post-myocardial infarction (MI) heart failure model.
Methods and Results: Rats were either subjected to left coronary artery ligation or sham sur-
gery. Rats with MI were left untreated (MI group) or long-acting EPO analogue darbepoetin 
treatment was started 3 weeks after MI in a low-dose (0.4 μg/kg/3 weeks, MI-EPO-low) 
or high-dose (40 μg/kg/3 weeks, MI-EPO-high). Echocardiography was used to measure 
the cardiac function during follow-up. After 9-weeks, hemodynamics, number of EPCs and 
capillary density were measured. Hematocrit increased in the MI-EPO-high, but not in MI-
EPO-low group (p<0.01). Both high- and low-dose EPO treatment resulted in preservation 
of left ventricular systolic function during follow-up, and improved cardiac contractility 
(dP/dtmax) and relaxation (dP/dtmin) at 9-weeks, compared to MI group (all p<0.05). In addi-
tion, in EPO-treated groups the number of circulating EPCs was significantly increased (MI-
EPO-high: 82 [66-147] and MI-EPO-low: 67 [55-107] vs. MI: 23 [19-33] cells/high-power 
field; both p<0.01). This was associated with a 33% increase in capillary density in MI-EPO-
high (p<0.01) and 20% in MI-EPO-low (p<0.05), compared to MI group.
Conclusions: EPO treatment preserves cardiac function in post-MI heart failure, even in doses 
not affecting hematocrit level. This is associated with raised number of circulating EPCs and 
an increased capillary density.
Introduction
The classical role of erythropoietin (EPO) is related to its hematopoietic effects. Production of 
EPO in the kidney is upregulated in response to lower blood oxygen levels. EPO acts as a major 
regulator of erythropoiesis, by increasing survival and promoting proliferation of erythroid 
precursor cells. 
Recently, several non-hematopoietic effects of EPO have been reported. EPO was shown to 
render vascular protection in various experimental models of ischemia, including stroke and 
myocardial infarction 1. During ex-vivo ischemia-reperfusion in isolated rat hearts, EPO perfu-
sion improved cardiac function and increased coronary flow 2,3. Acute, systemic treatment 
with EPO, in a rodent ischemia-reperfusion model, substantially reduced infarct size and de-
creased myocardial apoptosis 4, even when EPO was administered after reperfusion 5,6. 
Another important pleiotropic effect of EPO is the promotion of postnatal angiogenesis and 
vasculogenesis. Previously, expression of EPO-receptor on endothelial cells has been reported 3 
and EPO was shown to stimulate endothelial cell proliferation and differentiation into vascular 
structures 7. Recent studies demonstrated that circulating endothelial progenitor cells (EPCs) 
are involved in neovascularization and differentiate into endothelial cells in situ 8,9. In a study 
of Heeschen et al., EPO was shown to increase the number of circulating EPCs in the peripheral 
blood 10. Moreover, treatment with EPO significantly increased inflammation- and ischemia-
induced neovascularization 10. In heart failure patients, chronic EPO treatment was associated 
with an increase in the adhesive and proliferative properties of circulating EPCs 11.Low-dose erythropoietin attenuates heart failure 97
Recently, we assessed the effects of EPO treatment in a rat model of post-myocardial infarc-
tion (MI) heart failure. In this study, prolonged high-dose EPO treatment was associated with 
improved cardiac function and restored capillary density to sham values, indicating actual 
capillary growth 12. 
However, because high-dose EPO treatment is also associated with increased hematocrit val-
ues, the observed beneficial effects may, at least to some extend, be related to the increased 
oxygen-carrying capacity of blood. In the clinical situation, repeated therapy with high-dose 
EPO could lead to unwanted elevation of hematocrit, coupled with higher risk for thrombosis 
and hypertension. In addition, the existence of different receptors that mediate the effects of 
EPO in distinct tissues 13, may suggest also different dose-response relationships for the vari-
ous protective effects.
Therefore, we studied the effects of high- and low-dose EPO treatment on cardiac function 
over time, EPCs mobilization and neovascularization in a post-MI heart failure.
Methods
Animals
We used male Sprague Dawley rats weighing 270-330 g (Harlan, Zeist, The Netherlands). 
Animals were fed ad libitum, and housed in groups of four to five rats, according to institu-
tional rules with 12:12 hours light-dark cycles. The experimental protocol was approved by 
the Animal Ethical Committee of the University of Groningen. 
Design of the study
Rats were either subjected to left coronary artery ligation (n=63) or sham surgery (n=11). 
Rats with MI were allocated to 3 groups: control (MI) and two EPO treatment groups with 
different dosages of long-acting EPO analogue darbepoetin: 40 μg/kg (MI-EPO-high) and 
0.4 μg/kg (MI-EPO-low). Darbepoetin-alpha (Aranesp, Amgen Inc., Thousands Oaks, CA, 
USA) was administered intraperitoneally, once every three weeks, starting three weeks after 
the coronary artery ligation, hence after the development of post-MI heart failure. Control 
(MI) and SHAM rats received corresponding injections of saline. The allocation of MI rats to 
different groups was based on echocardiography performed at week 3 (before the start of 
the therapy), groups were matched based on left ventricular (LV) end-diastolic diameter and 
LV fractional shortening.
The high dose of darbepoetin was based on our previous study 12, demonstrating increased 
neovascularization in this model, together with significant elevation of hematocrit levels. To 
avoid the effect of EPO treatment on hematocrit we included a low-dose EPO group, with 
100-times lower darbepoetin dosage (0.4 μg/kg/3 weeks), which in our pilot experiment 
did not cause elevation of hematocrit (data not shown).Hematocrit was measured at baseline 
and at week 3, 4, 6 and 9 after surgery. 98 Chapter 7
Myocardial infarction model
This model has been described previously 14. Briefly, rats were anesthetized with 2.5% isoflu-
rane and placed on a heating pad (370C). Animals were intubated and mechanically ventilated 
(Amsterdam Infant Ventilator, Hoek/Loos, Schiedam, The Netherlands; frequency 90/min) 
using room air enriched with 1.0 l/min oxygen. After left-side thoracotomy, MI was induced 
by ligating the proximal portion of the left coronary artery, beneath the left atrial appendage. 
In sham operated rats, the same surgery was performed, without ligating the suture. 
Echocardiographic measurements
Cardiac function was assessed by echocardiography (Vivid 7, GE Healthcare, Chalfont St. 
Giles, United Kingdom; equipped with a 10-Mhz phase array linear transducer) at baseline 
(before coronary artery ligation), at week 3 (before start of the therapy), 6 and 8. The echo-
cardiographic measurements were performed under general anesthesia with 2.5% isoflurane, 
by two researchers blinded for the treatment allocation. The rats were placed on a heating pad 
(370C) and transducer was applied parasternally to the shaved chest wall. The transducer was 
maneuvered to obtain both 2-dimensional (2D) images in parasternal long-axis and short-
axis view and 2-D guided M-mode tracing. Long axis views were obtained, ensuring that the 
mitral and aortic valves and the apex were visualized. Short axis views were recorded at the 
level of mid-papillary muscles. LV end-systolic diameter (LVESD) and LV end-diastolic diam-
eter (LVEDD) were measured from the M-mode and calculated as an average from short- and 
long-axis view. LV fractional shortening (FS %) was calculated as FS= (LVEDD-LVESD)/LVEDD 
x 100. LV ejection fraction (EF %) was calculated using the Teichholz method of estimated 
LV volumes 15.
Hemodynamic measurements
After nine weeks rats were anesthetized as described above. Microtip pressure transducer 
(Millar Instr. Inc., Houston, Texas, USA) was inserted into the left ventricular cavity via the 
right carotid artery. After a 3-min period of stabilization, heart rate (HR), left ventricular 
systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and developed left 
ventricular pressure (dLVP=LVSP-LVEDP) were measured. As indices of contractility and re-
laxation, the maximal rates of increase and decrease in LVP (dP/dtmax and dP/dtmin) were 
determined. The catheter was retracted into the aortic arch and arterial systolic and diastolic 
blood pressures (SBP, DBP) were recorded. 
Infarct size
After hemodynamic measurements, hearts were rapidly excised and weighed. Mid-papillary 
slices were prepared for immunohistochemistry. Slices were fixed in 4% paraformaldehyde 
and paraffin-embedded. Infarct size was determined by planimetry at mid-ventricular levels in 
transverse slices on picrosirius red/fast green–stained sections. Infarct size was expressed as the 
percentage of scar length to total left ventricular circumference, as described previously 16,17. 
Blood derived endothelial progenitor cells
Full blood was collected in heparine tubes (17 IU/ml). Mononuclear cells were isolated us-
ing Histopaque-1083 (Sigma Chemical, St. Louis, MO, USA) according to the instructions as 
supplied by the manufacturer and counted on microcellcounter (Sysmex F-800, Toa Medical 
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precoated 24-well plates (BD BioCoat, Bedford, MA, USA) in EndoCult medium (StemCell 
Technologies, London, UK) supplemented with Penicillin (100U/mL) and Streptomycin 
(100μg/mL). After 6 days, adherent cells were washed with medium, incubated with 1,1’-
dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-labeled  acetylated  LDL  (10μg/mL  Dil 
AcLDL; Molecular Probes, Invitrogen, Carlsbad, CA, USA) for 12 hours, fixed with 1% para-
formaldehyde for 10 minutes, and counterstained with fluorescein isothyiocyanate-labeled 
Griffonia (bandeiraea) simplicifolia lectin I, isolectin B4 (lectin, 10 μg/mL; Vector Laboratories, Bur-
lingame, CA, USA). Images were captured by an inverted fluorescence microscope (Axiovert 
135 M, Carl Zeiss, Jena, Germany). Cells double positive for DiI AcLDL and lectin staining 
were considered EPCs and counted in high-power fields with the co-localization analysis 
(Image-Pro Plus for Windows, version 4.5.0.29). For every rat an average number of circulat-
ing EPCs was calculated from 4-5 high-power fields.
Capillary density
To visualize the capillaries in the myocardium of the LV free wall, endothelial cells were 
stained with biotin-labeled Lectin GSL (1:100; Sigma-Aldrich, St. Louis, Missouri, USA), as 
previously described 14. Since lectins stain not only capillaries but other vessels as well, a size 
criterion of 10 μm was used to exclude small arterioles and venules. Image analysis (Image-
Pro Plus for Windows, version 4.5.0.29) was used to measure capillary density, calculated as 
the number of capillaries per tissue area (mm2). The measured total tissue area was corrected 
for the remaining interstitial space.
Statistical analysis
Data are presented as mean ± SEM, or as median ± IQR (25th and 75th percentile) depending 
on their distribution. Differences among groups were tested using one-way analysis of vari-
ance, followed by LSD post-hoc analysis if normally distributed, and by Kruskal-Wallis test 
if skewed distributed. Correlation analysis was performed with Spearman’s correlation test. 
All reported probability values were 2-tailed, and a p-value <0.05 was considered statistically 
significant. All statistical analyses were performed with SPSS version 11.0.
Results
Mortality and general characteristics
Overall 24-hour mortality following the MI was 41%. No mortality was observed in sham-
operated rats. Five additional MI rats died during the 9-week long follow-up (2 in MI group, 
1 in MI-EPO-high and 2 in MI-EPO-low group).
General characteristics after nine weeks are shown in table 1. Two rats (1 in MI and 1 in 
MI-EPO-high group) had infarct size < 25%. These were excluded from further analysis. 
LV-infarct size (% of LV) was comparable between all MI groups (table 1).  Body weight was 
significantly higher only in the MI-EPO-low group (table 1). 
The heart weight (HW) to body weight ratio was significantly increased in the rats with MI 
compared to the sham rats (all p<0.05; table 1). A lower HW to body weight compared to 
MI group was observed in MI-EPO-high and MI-EPO-low groups (both p<0.05), suggesting 
diminished cardiac hypertrophy after MI. 100 Chapter 7
Low-dose EPO does not increase hematocrit
The changes of the hematocrit throughout the experiment are shown in table 1. Only in the 
MI-EPO-high group the treatment with high-dose EPO led to significant increase in hema-
tocrit levels, which persisted throughout the experiment. Importantly, hematocrit levels in 
MI-EPO-low group were similar to those of MI and sham groups.
Low-dose EPO improves cardiac function
Serial echocardiographic parameters are presented in figure 1. Baseline echocardiographic 
measurements of the LV size and function did not differ among groups before the coronary 
artery ligation. Induction of MI led to a significant enlargement of LVEDD and deterioration 
of LV performance (fractional shortening and ejection fraction) at 3 weeks. During treatment 
follow-up, LV performance (both EF and FS) was significantly better in both MI-EPO-high 
and MI-EPO-low group, as compared to control. While the deterioration of LV function pro-
gressed gradually in the MI group throughout the remaining 6 weeks, it remained stable after 
the initiation of EPO treatment in both the MI-EPO-high and MI-EPO-low group. Treatment 
with high-dose EPO prevented the progression of LV dilation (LVEDD), when compared to 
MI group at week 6 and 8 (both p<0.05). On the contrary low-dose EPO treatment did not 
decelerate the LV dilation after the MI. 
To further evaluate the hemodynamic profile of all experimental groups, invasive pressure 
Table 1. Characteristics of the experimental groups
Sham MI MI-EPO-high MI-EPO-low
General
n
Infarct size
    11
    -
    10
  45.5±3.6
     10
  46.7±1.5
        9
   50.0±3.2
Hemodynamics
Heart rate (bpm)
LVSP (mmHg)
LVEDP (mmHg)
SBP (mmHg)
DBP (mmHg)
   321±6
130±3
    9.8±0.6
127±3
     81±2
318±8
   104±6†
        23.5±3.7†
  102±5†
            73±3*
339±7
       119±3*§
        15.7±2.0‡
        115±3*‡
    83±3§
312±7
     115±4†
      18.8±2.3*
      113±4*
      80±2
Body/organ weight
BW (g)
Heart weight/BW (mg/g)
  410±6
      4.5±0.1
   402±12
            6.0±0.3†
 416±8
              5.3±0.1†‡
     442±8*§
           5.3±0.3*‡
Hematocrit
Baseline (%)
Week 3 (%)
Week 4 (%)
Week 6 (%)
Week 9 (%)
      48±0.9
      49±0.8
       51±0.9
      49±0.8
       44±0.6
            46±0.7
           50±0.7
             51±0.8
           50±1.0
    44±0.6
        48±0.6
        49±0.4
           64±1.1†§
              56±0.6†§
              53±1.4†§
    48±0.7
    50±0.5
    52±0.7
       51±0.5
     42±0.9
Data are presented as mean ± SEM; n indicates number of animals. bpm, beats per minute; LVSP, left ventricular sys-
tolic pressure; LVEDP, left ventricular end-diastolic pressure; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; BW, bodyweight. *p<0.05; †p<0.01 vs. Sham; ‡p<0.05, §p<0.01 vs. MI.Low-dose erythropoietin attenuates heart failure 101
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Figure 1a. Changes in echocardiographic indices of LV size and function during 8-weeks follow-up after coronary 
artery ligation. LVEDD indicates left ventricular end-diastolic diameter. * p<0.05 vs. MI, ** p<0.01 vs. MI. 1b. M-mode 
echocardiographic picture of a sham rat with calculation of LV size (left picture); 2D-picture of long axis in a rat after 
MI (right picture); LVEDD=left ventricular end-diastolic diameter; LVESD=left ventricular end-systolic diameter. 
measurements were performed 9 weeks after the surgery, directly before the rats were sacri-
ficed. Myocardial contractility (dP/dtmax) and myocardial relaxation (dP/dtmax) were both im-
paired in all MI groups compared to the sham group (all p<0.05). Both low- and high-dose 
EPO treatments resulted in better contractility and relaxation compared to MI (all p<0.05; 
figure 2). LVSP and developed LVP (dLVP) were both decreased in all MI groups compared 
to sham operated rats (p<0.05 for all). MI-EPO-high showed a significantly higher LVSP 
(table 1) and dLVP (figure 2), compared to MI (both p<0.01). Low-dose of EPO resulted in 
a 17% higher dLVP (p<0.05; figure 2), and a trend towards elevation of LVSP, compared to 
control group (p=0.07; table 1). LVEDP was elevated in MI-group compared to sham oper-
ated rats (p<0.01; table 1). In the MI-EPO-high group the LVEDP was 34% (p<0.05) and in 
the MI-EPO-low group 20% (p=NS) lower, compared to MI. Systolic blood pressure (SBP) 102 Chapter 7
was significantly lower in all MI groups compared to sham. SBP was significantly higher in 
MI-EPO-high, compared to MI group (p<0.05). The diastolic blood pressure (DBP) was 
lower compared to sham only in the control MI group (p<0.05). In both MI-EPO-high 
and MI-EPO-low, DBP was similar to that of sham group. No significant differences were 
observed in heart rate.
EPO dose-dependently increases circulating endothelial progenitor cells 
Induction of MI led to a decrease in the number of peripheral EPCs, at 9 weeks (23.2 [18.8-
32.8] in MI-group vs. 57.2 [35.0-59.8] per high-power field in sham group; p<0.05). 
Treatment with both high- and low-dose EPO resulted in a 3.6- and 2.9-fold increase in the 
number of circulating EPCs, respectively, compared to MI group (both p<0.01; figure 3).
Low- and high-dose EPO treatment increases capillary density
Capillaries stained with lectin were clearly discernable in the myocardium. Figure 4B shows 
representative photomicrographs of the four different groups. Capillary density was sig-
nificantly reduced in MI compared to sham-group (p<0.01). High-dose EPO treatment pre-
vented the decrease in capillary density after induction of MI and restored it to sham values, 
as shown in Figure 4A (p=NS vs. sham). In this group (MI-EPO-high) we observed a 33% 
increase in capillary density compared to MI group (p<0.01). Treatment with low-dose EPO 
resulted in a 20% higher capillary density (p<0.05). The differences between MI-EPO-high 
and MI-EPO-low group were not statistically significant.
In order to relate mobilization of EPCs to increased capillarization, correlations were deter-
mined. We observed a positive correlation between the number of capillaries per mm2 and 
the number of peripheral EPCs (r=0.32; p<0.05), which was even stronger in the rats sub-
jected to coronary artery ligation (r=0.59; p<0.01).
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Figure 2. Effects of myocardial infarction and different doses of EPO treatment on hemodynamic parameters. 
dLVP indicates developed left ventricular pressure; dP/dtmax and dP/dtmin, maximal rate of increase and decrease of 
ventricular pressure, respectively. * p<0.05 vs. MI, ** p<0.01 vs. MI.Low-dose erythropoietin attenuates heart failure 103
Discussion
In the present study, we examined the effects of high- and low-dose EPO treatment on 
cardiac function in a post-MI heart failure model. We show that both treatments attenu-
ate post-MI remodeling and improve cardiac function. Furthermore, this is associated with 
mobilization of endothelial progenitor cells and increased capillary density. Recently, numer-
ous experimental studies have demonstrated important non-hematopoietic functions of EPO, 
such as protection against ischemic injury in various tissues. In the first in vivo study on the 
EPO effects in the heart, Calvillo et al 18, employed a rat model of coronary ischemia-reperfu-
sion. Administration of EPO (5.000 IU/kg/day) for seven consecutive days after reperfusion 
reduced the loss of cardiomyocytes by 50%, an extent sufficient to normalize hemodynamic 
function. However, the hematocrit increased by 20-30% by the end of the study, and to some 
extent, such a change could lead to improved cardiac function merely by improving the de-
livery of oxygen. In a study by Parsa et al. 19, administration of high-dose EPO (5.000 IU/kg) 
reduced the infarct size both after ischemia-reperfusion, as well as permanent coronary oc-
clusion, but resulted in a 20% increase in hematocrit by day 4. Mechanism behind this acute 
cardioprotective effect of EPO is probably related to inhibition of apoptosis 5,20.
In clinics, current therapy in patients after MI is focused on prevention of ventricular remod-
eling and development of heart failure. Myocardial regeneration may offer possibilities that 
could improve cardiac function in these patients 21.  Although cardiomyocytes proliferation 
after ischemic injury seems limited, the formation of new vessels in the non-infarcted part 
of the ventricle could lead to an improvement of function and attenuation of ventricular 
remodeling 22,23. 
In addition to its anti-apoptotic properties during acute ischemic injury, EPO was recently 
shown to mobilize EPCs from the bone marrow, which was associated with neovasculariza-
tion (vasculogenesis) of  ischemic tissue 10. EPO has also been shown to stimulate prolifera-
tion of endothelial cells in situ (angiogenesis) 24. In a rat aortic ring model, EPO induced vas-
cular sprouting 25. In human cultured myocardial tissue, EPO stimulated capillary outgrowth 
comparable to VEGF 26.
The effect of EPO on the formation of new vessels has also been observed in an experimental 
model of stroke. EPO treatment, initiated 24 hours after induction of stroke, enhanced neo-
vascularization and improved neurological function, while it did not significantly influence 
infarct size  27. In this study, high-dose EPO treatment for seven consecutive days (5.000-
10.000 IU/kg/day) increased the density of microvessels at the stroke boundary (ischemic 
penumbra), but it also resulted in a 44% increase in hematocrit level.
We addressed this issue in the heart, evaluating the effect of EPO treatment on new vascular 
formation in an experimental heart failure model 12. Rats were subjected to coronary artery 
ligation and therapy with high-dose EPO analogue darbepoetin (40 μg/kg/3 weeks) was 
initiated 3-weeks post-MI. Although not reducing infarct size, EPO treatment significantly 
improved cardiac function. This improvement was coupled to increased capillary density 
and capillary-to-myocyte ratio, indicating neovascularization. Furthermore, these beneficial 
effects were also associated with increased percentage of alpha-MHC (myosine-heavy chain) 
isoforms, a molecular marker of enhanced myocardial contractility.
However, the dosages used in the previous studies, when applied to clinical situation, could 
cause EPO overdose which may lead to hypertension, seizures, vascular thrombosis and death, 
possibly related to abruptly increased hematocrit values 28. This could be of potential concern 104 Chapter 7
in patients with already elevated cardiovascular risk.
In our study, we chose a low-dose EPO treatment to avoid elevation of hematocrit, and con-
sequently the changes in rheology and oxygen-binding capacity of the blood, which could 
both influence our results. We also included a group with a high EPO dose (MI-EPO-high), 
leading to a marked hematocrit elevation, which effects on cardiac function in post-MI heart 
failure were already established 12. The low dose of EPO was two order of magnitude lower 
compared to high dose (40 vs. 0.4 μg/kg/3 weeks). We did not observe any differences in 
hematocrit levels between the MI-EPO-low and both saline treated groups (MI and sham), 
while in MI-EPO-high the hematocrit remained significantly elevated during the treatment 
follow-up.
Treatment with low-dose EPO prevented the deterioration of LV function over time, as as-
sessed by LV ejection fraction and fractional shortening, serially evaluated by echocardiogra-
phy. However, low-dose EPO, as opposed to high-dose, did not avoid the progression of LV 
dilation. While this could mean a dose-dependent effect of EPO, bigger infarct size in MI-
EPO-low group, although not significantly different from other groups, could have averted 
the beneficial effects of EPO on LV geometry. Low-dose EPO treatment thus, in spite of ad-
vanced LV dilation, improves contractile properties of the non-infarcted part of the myocar-
dium. Importantly, this effect was also confirmed by invasive hemodynamic measurements at 
the end of the study. Although the treatment with high-dose resulted in noticeable improved 
cardiac function, low-dose treatment also caused a significant enhancement of developed 
LVP, together with contractility and relaxation indices of the LV.
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A lower heart weight to body weight ratio in MI-EPO-high and MI-EPO-low group com-
pared to control also indicates attenuation of cardiac hypertrophy by both EPO treatment 
regimens and beneficial effects on post-MI cardiac remodeling.
We confirmed the findings of our previous experiments, that high-dose EPO treatment in-
creases capillary density, promoting neovascularization after ischemic injury in the heart. In 
addition, low-dose EPO, although to a lesser extent, increased the capillary density by 20%. 
Both high- and low-dose EPO treatment increased the number of circulating EPCs. This is 
line with findings of Bahlmann et al.29, who found that darbepoetin stimulates bone marrow-
derived EPCs at doses that do not increase the hematocrit. Moreover, the increased number 
of EPCs was significantly correlated with the amount of capillaries per mm2, providing an 
interesting link between EPCs mobilization and increased capillarization in the heart.
Application of lower doses of EPO was also shown to confer vascular and tissue protection 
in the kidney 30. Low-dose darbepoetin treatment in a rat remnant kidney model improved 
the survival, ameliorated endothelial damage and preserved renal function, without increase 
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in hematocrit levels. Another option to avoid the negative effects of chronic EPO therapy on 
hematocrit values, could be the use of recently discovered nonhematopoietic derivates of 
EPO, retaining the tissue protecting property, without undesired effect on hematopoiesis 31. 
The possibility to separate the hematopoietic and tissue-protective effect could be explained 
through interaction of EPO with different receptors in various tissues 32. However, the role 
of these receptors in EPCs stimulation is unknown, and thus the regenerative capacity of the 
novel EPO derivates may be attenuated by reduced mobilization of EPCs.
In summary, low-dose EPO treatment preserves cardiac function in post-MI heart failure. 
This is associated with raised number of circulating EPCs and an increased capillary density. 
Although time-limited treatment with high-dose EPO may be beneficial and safe during 
acute ischemic injury, if prolonged therapy is required (heart failure), drug regimens using 
low-dose EPO may be more suitable in avoiding the adverse effects of the treatment.
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Myocardial infarction accounts for increasing morbidity and mortality in western countries. 
Although the early reperfusion therapy significantly improves the clinical outcome, addi-
tional myocardial protection may be needed to limit reperfusion damage.
Various growth factors have been found to provide cell protection during reperfusion of the 
ischemic heart. Recently, hematopoetic hormone- erythropoietin (EPO) has been implicated 
in cardioprotection. 
EPO is produced primarily in the kidney and its actions are mediated via a specific interac-
tion with EPO-receptor (EPO-R). Major intracellular transduction pathways involved in EPO 
signalling include STAT-5, MAP and Akt kinases (1). Activation of these pathways is associ-
ated with cellular protection, predominantly due to inhibition of apoptosis. Presence of EPO 
in bone-marrow thus salvages the precursor cells from programmed death, enabling their 
proliferation and differentiation (2). 
In recent years, expression of functional EPO-R has also been demonstrated in non-hema-
topoietic cells and organs including brain, kidney and cardiovascular tissue. These findings 
indicate that besides stimulating hematopoiesis, EPO may play a role as a pleiotropic survival 
and growth factor (3). 
Many experimental studies have shown the protective effect of EPO in the brain. Systemic 
administration of EPO before or up to 6hours after focal brain ischemia reduced the infarct 
volume by 50-75% (4). In most models, inhibition of apoptosis was documented as the 
underlying mechanism of observed neuroprotection (5). In the first clinical, randomized, 
double-blind trial, EPO was given to patients with ischemic stroke presenting within 8 hours 
after onset of symptoms (6). In spite of the relatively small number of patients in this study, 
EPO administration in high-doses (entire dose 100.000 IU/ given in three days) proved to 
be both safe and beneficial. Patients randomized to the EPO group showed significant im-
provement in clinical outcome parameters and a trend towards smaller infarct sizes.
Recently, evidence is accumulating for a protective role of EPO in the heart. In a study per-
formed by our group, presence of a functional EPO-R in rat heart was established (7). Fur-
thermore, perfusion of isolated rat hearts with EPO during ischemia/ reperfusion (I/R) 
improved left ventricular function and limited cellular damage. Cai et al (8) showed that 
immediate protection against I/R provided by EPO is specifically mediated through an Akt-
dependent pathway.
In vivo, Parsa et al evaluated the effects of EPO in a rabbit model of both I/R and permanent 
coronary occlusion. In both conditions, administration of EPO (5.000 IU/kg) led to infarct 
size reduction associated with inhibition of apoptosis (9).
However, two clinically important questions remained to be answered. What is the  time 
window of opportunity for EPO administration during ischemic insult and what is the mini-
mum dose that would still render cardioprotection. Our group has tried to answer the first 
question, showing the extension of the EPO cardioprotective effect beyond the start of re-
perfusion (10).
In this issue of Cardiovascular Drugs and Therapy, Hirata et al. (11) report that EPO treatment 
in a canine model of I/R reduced infarct size across a broad dose range from 100-1000 
IU/kg. This study shows EPO treatment protects against I/R injury in the heart in a dose de-
pendent manner. It does so, at least to some extent, by reducing apoptosis. The authors also 
demonstrate, for the first time in vivo, the crucial role the Akt-pathway plays in the observed 
effects. However, the proposed direct anti-arrhythmogenic role of EPO should be considered 
cautiously, as it may well have been directly the result of infarct size reduction.Erythropoietin: From Hematopoiesis to Cardioprotection 115
Besides its acute cardioprotective effects, through inhibition of apoptosis, EPO may also 
influence formation of new vessels after ischemic injury. In vitro, stimulation of cultured 
endothelial cells with EPO results in proliferation and formation of vascular structures (12). 
Jaquet et al. compared the angiogenic properties of EPO with vascular endothelial growth 
factor (VEGF) on endothelial cells derived from human myocardial tissue. They found that 
both proteins exhibited equal angiogenic properties, indicating a possible pro-angiogenic 
effect of EPO (13). This was further studied in a rat model of stroke. EPO treatment, initiated 
24 hours after occlusion of the middle cerebral artery, enhanced angiogenesis and improved 
neurological function, while it did not significantly influence infarct size (14). However, 
the mechanisms behind the effects of EPO on neovascularisation remain largely unknown. 
Very recently, Tepper et al. showed for the first time that newly formed vessels in hypoxic tis-
sue were constructed entirely of bone marrow-derived endothelial progenitor cells (EPCs), 
known as vasculogenesis (15). Since EPO is a powerful stimulator of the mobilisation of 
endothelial progenitor cells from the bone marrow, it is tempting to speculate that the ef-
fects observed with EPO treatment might be related to the mobilisation of EPCs. However, 
the neovascularisation could also be related to sprouting of existing endothelial cells (i.e. 
angiogenesis). Further research will be needed to elucidate the effects of EPO on neovascu-
larisation and the role of angiogenesis and/or vasculogenesis in this process. 
The hematopoiesis stimulating function of EPO has been used for almost two decades in 
treating patients with renal anemia. Indications for EPO treatment have broadened in the last 
few years to include other forms of anemia, where EPO deficiency is not primarily causa-
tive. In clinical cardiology, EPO has already been used in anemic patients with chronic heart 
failure (CHF). Anemia is common in patients with CHF and related to an increased morbid-
ity and mortality (16). Furthermore, not only anemia, but also elevated endogenous EPO 
levels are independently associated with an impaired outcome in CHF (17). Normalisation 
of hemoglobin levels in mildly anemic CHF patients has a positive effect on left ventricular 
ejection fraction (18) and peak VO2 (19). In addition to correction of anemia, other non-
hematopoietic effects of EPO, as described above, might play a role in the improvement 
observed in patients with CHF treated with EPO. 
In summary, EPO is increasingly regarded a general tissue-protective agent. The new study of 
Hirata et al. in this issue of the journal provides additional evidence that EPO is cardioprotec-
tive even at low doses. Considering the high safety profile of EPO, future clinical studies in 
patients with acute coronary syndromes are a logical next step in broadening the indications 
for EPO therapy: from hematopoiesis stimulation to cardioprotection.Chapter 8 116
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Summary
The purpose of the studies presented in this thesis was to investigate the origin of anemia in 
CHF patients and to study the influence of anemia and endogenous EPO levels on mortality 
in CHF (part one). Further, we investigated the ancillary properties of exogenous EPO on 
cardioprotection, besides the well-known hematopoietic effects of EPO (part two).
Etiology of anemia in CHF
It has been established in several studies that anemia is an independent prognostic marker for 
mortality in CHF patients. Although anemia is common in patients with CHF, the origin of 
anemia in CHF is mostly unknown. Several potential mechanisms may be involved (discussed 
in chapter 2). 
Chronic renal failure (CRF) is likely to be an important contributory factor in the anemia 
observed in CHF patients. In many patients with end-stage renal disease, anemia is a common 
feature. In turn, CHF can cause CRF due to a decreased cardiac output and relative renal vaso-
constriction, leading to chronic renal ischemia and subsequently inducing anemia. The links 
between CRF, CHF and anemia have been called the Cardio-Renal-Anemia syndrome(1). 
Since many patients with CHF have a normal or only slightly impaired renal function, other 
factors probably play a role in the presence of anemia in CHF. Hematinic deficiencies may 
be implicated to the anemia observed in CHF patients. There may be reduced uptake of 
iron, folate acid and vitamin B12, related with poor nutrition, malabsorption and cardiac 
cachexia(2). Furthermore, the use of aspirin and oral anticoagulation can lead to microscopic 
amounts of gastrointestinal blood loss, contributing to the anemia. A recent study in the 
UK demonstrated that only a minority of CHF patients had renal impairment or underlying 
hematinic deficiencies(3). This was confirmed by Witte et al, who showed that less than one 
third of the CHF patients were iron, folate acid or vitamin B12 deficient(4). 
Anemia can originate from increased plasma volume (hemodilution), due to salt and water 
retention in CHF patients(5). Lower hemoglobin levels are also frequently observed in in-
flammatory conditions. It has been shown that patients with CHF express elevated levels of 
TNF-alpha, which in turn may reduce the hematopoietic proliferation. Experimental data 
support this hypothesis. The proliferative capacity of the progenitor cells in mice with heart 
failure was found reduced to approximately 50% of control(6). 
Treatment of CHF might induce anemia. It has been shown that intervention in the renin 
angiotensin system (RAS) may be related to reduced hematopoietic activity. A recent sub-
study of the Studies Of Left Ventricular Dysfunction (SOLVD), demonstrated convincingly 
that enalapril significantly increased the odds of developing anemia by 56% in patients with 
CHF(7). To extend on these findings, a study in 98 CHF patients was performed to investigate 
the effects of ACE-inhibitor therapy on hematopoietic proliferation (Chapter 3). Almost 60% 
of the anemic patients had an unexplained anemia (normal hematinics and no renal failure). 
Serum of these anemic CHF patients inhibited in vitro the proliferation of bone marrow de-
rived erythropoietic progenitor cells of healthy donors by 17%. Levels of the hematopoiesis 
inhibitor Ac-SDKP, which is almost exclusively degraded by ACE, were significantly higher 
in anemic CHF patients. The clear correlation between Ac-SDKP levels and proliferation of 
erythroid progenitor cells suggests an inhibitory role of Ac-SDKP on hematopoiesis in CHF 
patients, which may explain the observed anemia in patients treated with ACE-inhibitors. Summary, conclusions and future directions 121
Anemia, Endogenous EPO and Survival
Few studies have been performed on the role of endogenous EPO levels. The relation be-
tween endogenous EPO levels and hemoglobin levels may give further insight into the pa-
thyphysiology of anemia in heart failure. It has been shown in populations with anemia of 
chronic disease, endogenous EPO levels are reported to be relatively low, compared to the 
degree of anemia(8;9). In CHF it has been observed that endogenous EPO levels are elevated, 
proportional to the severity of symptoms(10;11). In chapter 4 the impact of endogenous EPO 
levels on hemoglobin and survival was studied. Patients with mild to severe CHF and control 
patients were included. Multivariate analysis showed that plasma EPO and hemoglobin levels 
were independent predictors of survival. These findings were recently confirmed by others 
in a slightly larger CHF population(12). Furthermore, only a mild inverse correlation between 
EPO and hemoglobin levels could be observed in CHF patients, whereas the control group 
showed a clear significant inverse correlation, as expected. These findings may indicate a 
blunted EPO response relative to the hemoglobin levels. Further, it is tempting to speculate 
that due to the pro-inflammatory cytokines EPO resistance may occur in the bone marrow, 
requiring higher EPO levels to counterbalance the decreased sensitivity to EPO.
Pleiotropic effects of EPO
In response to lower oxygen levels, an upregulation of EPO occurs. EPO acts as a major regu-
lator of erythropoiesis, by promoting the survival and proliferation of erythroid precursor 
cells, due to its anti-apoptotic properties. These anti-apoptotic effects resulted in extensive 
research in the anti-apoptotic properties of EPO in various models of neurological damage, 
including ischemic stroke and subarachnoid hemorrhage(11;13-15). Since there are many simi-
larities between ischemia in the brain and the heart, recently studies have been conducted 
to evaluate its possible effect in cardiac ischemia(16-18). In chapter 5 the presence and func-
tionality of the EPO-receptor was studied by perfusing rat hearts with EPO or vehicle.  Im-
munohistochemistry in this ex vivo model revealed the presence of the EPO-R on endothelial 
cells, fibroblasts and to a lesser extent cardiomyocytes. Furthermore, perfusion with EPO 
resulted in an increase in the phosphorylated MAP kinases p42/p44, whereas no differences 
in phosphorylated STAT5 could be observed. In a low-flow ischemia/reperfusion experi-
mental setup EPO reduced the cellular damage by 56% during reperfusion and resulted in 
a significantly improved recovery of left ventricular pressure and coronary flow. Immuno-
histochemistry with staining against active-caspase 3 showed that EPO reduced apoptosis by 
approximately 15%. 
EPO in experimental Heart Failure
These findings prompted further research of the non-hematopoietic effects of EPO in CHF. 
Another important pleiotropic effect of EPO is associated with its ability to stimulate endothe-
lial cell proliferation(19). As shown in chapter 5, the EPO-receptor is expressed on endothelial 
cells. These findings support the in vivo data regarding the effects of EPO on neovasculariza-
tion. It has been shown in a rodent model of hind-limb ischemia, that EPO increases capillary 
density 1.6-fold(20). In chapter 6 we assessed the effects of EPO treatment in a rat model of 
post-myocardial infarction heart failure. This study demonstrated that EPO treatment in a rat 
model of heart failure improved cardiac function beyond its effect on infarct size reduction. 
It was shown that a single dose of EPO clearly improved cardiac performance, prolonged EPO 
treatment was associated with a further restoration of cardiac function. Mechanisms involved Chapter 9 122
in this process are most likely distinct from its acute cardioprotective effect. This is clearly 
demonstrated by the finding that EPO treatment, initiated three weeks after MI, although not 
reducing infarct size, significantly improved cardiac function, reflected by a 34% decrease 
in left ventricular end-diastolic pressure, and restoring N -ANP levels to sham values. Since 
the effect of EPO treatment in this group could not be explained by infarct size reduction, 
other properties of EPO should be considered to elucidate the observed beneficial effects of 
EPO in heart failure. In line with this finding, we found an increased capillary density and 
an increased capillary-to-myocyte ratio in the EPO treated groups, indicating actual capillary 
growth, which was related to myocardial function.
However, several questions remained unanswered. Since EPO treatment was also associated 
with an increased hematocrit value, the observed beneficial effects may, at least to some 
extend, be related to the increased oxygen-carrying capacity of blood. It has been shown 
that also lower doses of EPO resulted in vascular and kidney protection, without increasing 
hemoglobin levels(21). Further it was unclear when the improvement in cardiac function oc-
curred and whether EPO could mobilize endothelial progenitor cells (EPCs), which may be 
related to the neovascularization. To address these questions, we performed a similar study in 
which we included a second group treated with a low-dose EPO, besides the high-dose EPO 
(chapter 7). Echocardiography was used to subsequently measure the cardiac function dur-
ing follow-up. In this study we found that both high and low-dose EPO treatment resulted 
in consolidation of left ventricular systolic function during follow-up, while in the control 
group left ventricular systolic function deteriorated over time. Although the infarct size was 
similar in all MI groups, both EPO-treated groups showed an improved cardiac function. In 
addition high-dose and low-dose EPO treatment increased the number of peripheral EPCs. 
Both EPO treatments resulted in a higher capillary density in the spared myocardium. The 
low-dose EPO treatment did not increase the hematocrit, and therefore the observed benefi-
cial effects are entirely related to the non-hematopoietic effects of EPO. 
Future directions
Etiology of anemia in CHF 
In part 1 of this thesis the etiology of anemia in CHF is described. The finding that Ac-SDKP 
may explain the occurrence of anemia in CHF provides a new link between hematopoiesis 
and the RAS. Further evidence for an important role of Ac-SDKP in anemia was provided in 
anemic hemodialysis patients. They found that patients on hemodialysis with high Ac-SDKP 
levels required higher weekly EPO doses to prevent development of anemia(22). Therefore, 
it is interesting to speculate that in patients with CHF treated with ACE-inhibitors anemia 
will only develop when lower EPO levels exists in conjunction with higher Ac-SDKP levels. 
It follows that under these circumstances, the inhibitory effect of Ac-SDKP exceeds the pro-
liferative properties of EPO. Furthermore, one may hypothesize that the inhibitory effects 
of ACE-inhibitors on hematopoiesis can be prevented by the use of angiotensin receptor 
blockers in CHF patients. However, since angiotensin II stimulates the proliferation of ery-
throid-progenitor cells, treatment with angiotensin receptor blockers might also lower the 
hematopoietic activity (23). Theoretically, the combination of ACE-inhibitors and angiotensin 
receptor blockers may be deleterious for the hematopoietic proliferation activity. Clearly, 
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In addition, it remains speculative whether correction of anemia in CHF patients may lead to 
a reduced morbidity and mortality. Several small-scale trials showed beneficial effects of EPO 
treatment on exercise capacity, left ventricular function and hospital admission. However, it 
must be noted that these studies were not performed in a double-blinded manner, which 
may influence outcome(24;25). It also needs to be elucidated what the optimal hemoglobin 
target would be in anemic CHF patients, whether the hemoglobin targets used in renal 
anemia can be extrapolated to the CHF population and when EPO treatment should be 
initiated.  In addition, multi-center trials in CHF patients should be performed, to study the 
impact of EPO treatment on morbidity and mortality. At the present, treatment of anemia in 
patients with CHF is not the standard of care and EPO treatment should only be assessed in 
an investigational setting, not withstanding its important role in the management of renal 
anemia and the promising results of small scale (pre)-clinical trials.
Pleiotropic effect of EPO
Besides the direct hematopoietic effects of EPO, it has been shown that EPO possesses sev-
eral non hematopoietic effects, including neovascularization. However, it still needs to be 
elucidated whether the neovascularization is mainly related to proliferation of in situ endo-
thelial cells (i.e. angiogenesis) or is associated with vasculogenesis.  In a recent paper it has 
been shown that newly formed vessels in hypoxic tissue were constructed entirely of bone 
marrow-derived endothelial progenitor cells (EPCs), a process known as vasculogenesis(26). 
Since EPO is a powerful stimulator of the mobilization of endothelial progenitor cells from 
the bone marrow in CHF, as shown in chapter 7, it is tempting to speculate that the effects 
observed with EPO treatment might be related to the mobilization of EPCs. On the other 
hand, neovascularization could also be related to sprouting of existing endothelial cells. It has 
been shown that EPO is able to stimulate the proliferation of endothelial cells, in vitro and in 
vivo. To discern between vasculogenesis and angiogenesis transgenic studies would be needed 
in which wild-type rats will be lethally irradiated and bone marrow will be substituted from 
transgenic rats. By co-staining for an endothelial marker and a reporter protein, endothelial 
cells derived from the bone marrow can be detected. These studies will further increase our 
knowledge of the effects of EPO on neovascularization in CHF. 
There is limited evidence for pleitropic effects of EPO in human studies. One of the first 
studies, assessing the effects of EPO on infarct size reduction was performed by Ehrenreich 
and colleagues. In a double blind randomised proof-of-concept trial they investigated the 
safety and efficacy of EPO in stroke patients(27). Forty patients received either EPO or saline 
daily for 3 days after stroke. The investigators found an improvement in clinical outcome and 
a trend towards reduction in infarct size, assessed by MRI-scan, in the EPO treated patients. 
Recently, we performed a similar safety study in patients with acute myocardial infarction 
(manuscript in preparation). Twenty-two patients were randomized to EPO (darbopoetin 
300μg) or placebo. No adverse events were recorded during the 30-day follow up. In the EPO 
treated patients, only a non-significant increase in hemoglobin levels could be observed. In 
addition, EPO treatment was associated with elevated levels of endothelial progenitor cells. 
Larger scale clinical trials, assessing the effects of EPO on infarcts size and left ventricular 
function are warranted. The effects of EPO on endothelial progenitors might be of benefit 
in the treatment of CHF patients. Therefore further investigation is needed to provide more 
insight into the effects of EPO in CHF. Positron Emission Tomography (PET) might be a 
useful tool to study the effects of EPO on cardiac metabolism and myocardial blood flow and Chapter 9 124
its relation to endothelial progenitor cells. 
Recent studies in brain and heart focussed on EPO analogues without hematopoietic effects. 
One of these compounds is carbamylated EPO (C-EPO). Through carbamylation, which 
slightly modifies the lysine residues in EPO, a non-hematopoietic EPO is created which does 
not possess erythropoietic effects, but still renders tissue protection. In vivo studies in rodents 
showed that even high doses of C-EPO for longer periods of time did not result in an increase 
in hemoglobin values(28). However, it has been shown that C-EPO inhibits apoptosis, decreases 
infarct size and subsequently improves cardiac function in rats subjected to myocardial 
infarction(29). The development of these EPO derivates might be of potential benefit in the 
treatment of myocardial infarction and CHF in patients with normal hemoglobin levels. The 
discovery of these EPO analogues and the effects beneficial of low-dose EPO may shift the 
role of EPO from hematopoiesis to cardioprotection.Summary, conclusions and future directions 125
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Hartfalen is een complex van klachten en verschijnselen ten gevolge van een tekort schieten-
de pompfunctie van het hart. Patiënten met hartfalen hebben een hoog risico om te komen 
overlijden. In een recente studie is aangetoond dat het risico om tijdens het leven hartfalen te 
ontwikkelen 1 op 5 is voor zowel mannen als vrouwen. De etiologie van hartfalen is divers, 
maar de belangrijkste oorzaak is een doorgemaakt hartinfarct. Andere oorzaken voor het ont-
staan van hartfalen zijn: hypertensie, hartklep afwijkingen, myocarditis en cardiomyopathie.
Verschillende factoren zijn betrokken bij de prognose van hartfalen. Recent is bekend gewor-
den dat bloedarmoede (anemie) een onafhankelijke voorspeller is voor mortaliteit in pa-
tiënten met hartfalen. De incidentie van anemie hangt van verschillende factoren af. Een van 
de belangrijkste determinanten is de ernst van het hartfalen. Naar mate de ernst toeneemt, 
neemt ook de incidentie van anemie toe. Hoewel verschillende onderzoeken de prognosti-
sche waarde van anemia voor het voorspellen van mortaliteit beschrijven, is over de oorzaak 
van anemia in hartfalen weinig bekend. 
In hoofdstuk 3 van dit proefschrift tonen we aan dat in 60% van de patiënten met hartfalen 
en anemie geen verklaring voor de bloedarmoede kan worden gevonden. Deze patiënten 
hebben geen nierfunctie stoornissen of ijzer- en vitaminedeficiënties. Het serum van deze 
anemische patiënten met hartfalen remt de proliferatie van erythroïde voorloper cellen. Dit 
in tegenstelling tot niet anemische hartfalen patiënten en gezonde controle personen. De 
oorzaak van de remming komt door hogere spiegels van de hematopoëse remmer, N-acetyl-
seryl-aspartyl-lysyl-proline (Ac-SDKP), in het serum van anemische hartfalers. Ac-SDKP is 
een tetrapeptide dat uitsluitend door ACE wordt afgebroken. Daarnaast werd een duidelijke 
correlatie gevonden tussen de Ac-SDKP spiegels en de proliferatie van hematopoëtische voor-
loper cellen. Deze bevindingen koppelen het renine angiotensine systeem aan hematopoëse 
en verklaren deels het optreden van bloedarmoede bij patiënten met hartfalen. 
Er is weinig onderzoek gedaan naar de effecten van endogeen erythropoëtine (EPO) in pa-
tiënten met hartfalen. De relatie tussen hemoglobin en endogeen EPO kan meer inzicht 
geven in de pathofysiologie van anemie in patienten met hartfalen. In patienten met anemie 
door chronische ziekte is aangetoond dat EPO spiegels lager zijn dan men verwacht in relatie 
tot de ernst van de anemie. Dit zou een relatieve deficiëntie van EPO betekenen. In patiënten 
met hartfalen is in een tweetal onderzoeken aangetoond dat EPO spiegels stijgen als de ernst 
van het hartfalen toeneemt. In hoofdstuk 4 werd gekeken naar het effect van endogene EPO 
en hemoglobine spiegels op mortaliteit in patienten met hartfalen. Multivariate analyse liet 
zien dat endogeen EPO en hemoglobine beide onafhankelijke voorspellers zijn voor morta-
liteit in patiënten met mild tot ernstig hartfalen. Daarnaast vonden we in hartfalen patiën-
ten een zwakke correlatie tussen hemoglobin en EPO, terwijl in de controle groep (zonder 
hartfalen) een sterke correlatie tussen hemoglobine en EPO werd gezien. Deze bevindingen 
vormen een aanwijzing dat de EPO response in hartfalen patiënten verminderd is, in relatie 
tot de hemoglobine waarden. Een mogelijke verklaring hiervoor kan zijn dat pro-inflamma-
toire cytokines zorgen voor een EPO resistentie in het beenmerg. Hierdoor zijn hogere EPO 
spiegels nodig om de hematopoëse voldoende te stimuleren.
Naast de hematopoëtische effecten van EPO zijn er ook non-hematopoëtische effecten van 
EPO bekend. Een belangrijke eigenschap van EPO is het anti-apoptotische effect. In een expe-
rimenteel herseninfarct model is aangetoond dat EPO toediening zorgt voor een reductie van Nederlandse samenvatting 131
de infarctgrootte. Deze afname lijkt voor een belangrijk gedeelte te komen doordat EPO de 
apoptose remt. In hoofdstuk 5 laten we zien dat er een functionele EPO-receptor aanwezig 
is in het rattenhart. De EPO receptor komt voornamelijk tot expressie op endotheel cellen en 
fibroblasten. Daarnaast werd in een ‘low-flow’ ischemie/reperfusie experiment aangetoond 
dat EPO behandeling leidde tot een verbeterde hartfunctie en coronair doorstroming. Deze 
positieve effecten kunnen deels worden verklaard doordat EPO het aantal apoptotische cellen 
in het hart met 15% verminderde.
Deze bevindingen hebben geleid tot verder onderzoek naar de non-hematopoëtische effec-
ten van EPO in een experimenteel model voor hartfalen. Het is al eerder aangetoond dat EPO 
kan leiden tot proliferatie van gekweekte endotheel cellen. In een in vivo model van ischemie 
van de achterpoot van een rat, werd gezien dat EPO zorgde voor een toename in het aantal 
capillairen. In hoofdstuk 6 hebben we de effecten van EPO bestudeerd in een rattenmodel 
voor post-infarct hartfalen. In deze studie werd aangetoond dat EPO behandeling, gestart 
drie weken na het myocard infarct, niet leidde tot een infarctgrootte reductie, maar wel een 
significante verbetering van de hartfunctie gaf. EPO resulteerde in een significante verhoging 
van het aantal capillairen per vierkante millimeter en zorgde voor een toename van het aantal 
capillairen per cardiomyocyt. Deze bevindingen laten zien dat de verbetering van de hart-
functie mogelijk gerelateerd is aan neovascularisatie. 
Toch bleven er vele vragen onbeantwoord bij deze studie. EPO behandeling was namelijk 
ook geassocieerd met een significante stijging van de hematocriet. Een deel van de positieve 
effecten van EPO kunnen mogelijk verklaard worden door de verhoogde zuurstoftransport-
capaciteit van het bloed. In eerdere studies naar de effecten van EPO op nierprotectie werd 
al aangetoond dat lagere EPO dosering de nieren en de bloedvaten beschermden, zonder 
dat dit leidde tot een stijging van de hematocrit. Verder was het onbekend wanneer de ver-
betering in hartfunctie ontstond en of de verhoogde capillaire dichtheid gerelateerd was 
aan het vermogen van EPO om endotheel voorloper cellen te kunnen mobiliseren.Om deze 
onderzoeksvragen te kunnen beantwoorden hebben in hoofdstuk 7 naast de hoge dosis EPO 
ook een groep met een lage EPO dosering bestudeerd. Echocardiografie werd toegepast om 
sequentieel de hartfunctie te kunnen meten. In deze studie vonden we dat zowel de hoge als 
de lage dosering leidde tot een consolidatie van de hartfunctie, terwijl de hartfunctie in de 
onbehandelde controle groep in de tijd verslechterde. Hoewel infarctgrootte in alle groepen 
gelijk was, lieten beide EPO behandelde groepen een verbeterde hartfunctie zien. Daarnaast 
vonden we dat beide doseringen resulteerden in een toename van de circulerende endotheel 
voorloper cellen en leidden tot een hogere capillaire dichtheid. De lage EPO dosering zorgde 
niet tot een toename in de hematocriet. Hieruit kan worden geconcludeerd dat de effecten 
van de lage EPO dosering volledig zijn toe te schrijven aan de non-hematopoëtische eigen-
schappen van EPO.132
Discussie
Oorzaak van anemie in chronisch hartfalen
In het eerste gedeelte van dit proefschrift wordt de etiologie van anemie in hartfalen patiën-
ten bestudeerd. Serum van  anemische hartfalen patiënten, met hogere Ac-SDKP spiegels, 
remde de proliferatie van hematopoëtische voorlopercellen. Hierin wordt voor het eerst de 
link tussen hematopoëse en het renine angiotensine systeem beschreven in patiënten met 
hartfalen. Dat Ac-SDKP een belangrijke rol speelt in het ontstaan van anemie werd ook aan-
getoond in dialyse patiënten. Hemodialyse patiënten met hogere Ac-SDKP spiegels hadden 
een hogere dosering van exogeen EPO nodig om de streefwaarden van het hemoglobine te 
bereiken. Mogelijk dat ACE-remmer gebruik bij patiënten met hartfalen pas tot anemie zal 
leiden, als er ook relatief lage endogene EPO spiegels aanwezig zijn. In deze conditie is het 
remmende effect van Ac-SDKP groter dan het stimulerende effect van EPO. Daarnaast zou 
het kunnen dat de negatieve effecten van ACE-remmers op de hematopoëse kunnen worden 
voorkomen door het gebruik van angiotensine receptor blokkers, die de ACE-activiteit niet 
verlagen en daardoor geen effect van Ac-SDKP spiegels hebben. Aan de andere kant is ook 
bekend dat angiotensine II leidt tot stimulering van de proliferatie van hematopoëtische 
voorlopercellen. Het blokkeren van de angiotensine II receptor kan mogelijkerwijs de pro-
liferatie remmen. Theoretisch zou men kunnen stellen dat de combinatie van ACE-remmers 
en angiotensine receptor blokkers de proliferatie van hematopoëtische voorlopercellen het 
meest zou remmen. Meer onderzoek naar de effecten van beide geneesmiddelen op het he-
matopoëtische systeem zijn nodig om deze vragen te kunnen beantwoorden.
Verder is het op dit moment niet duidelijk of het corrigeren van de anemie in hartfalen pa-
tiënten ook daadwerkelijk leidt tot een reductie in morbiditeit en mortaliteit. Enkele kleine 
onderzoeken lieten wel een positief effect zien op uithoudingsvermogen, linker ventrikel 
functie en het aantal ziekenhuis opnames. Deze onderzoeken werden echter niet dubbel-
blind gerandomiseerd uitgevoerd, hetgeen een effect op de uitkomst kan hebben. Vooralsnog 
is het wachten op een groot dubbel blind ‘multi-center’ onderzoek, om het effect van EPO 
op mortaliteit en morbiditeit te analyseren. Momenteel behoort de EPO behandeling van 
anemische hartfalen patiënten niet tot de standaard zorg, hetgeen geen afbreuk doet aan 
de belangrijke rol van EPO in de therapie van renale anemie en de positieve resultaten van 
kleinschalige (pre)klinische studies in hartfalen.
Pleiotrope effecten van EPO
Naast de hematopoëtische effecten van EPO, bezit EPO ook non-hematopoëtische eigen-
schappen zoals neovascularisatie. Op dit moment is niet bekend of het effect van EPO op 
endotheel cellen leidt tot lokale proliferatie (angiogenese) of dat EPO zorgt voor vasculo-
genese. Recent onderzoek heeft laten zien dat nieuw gevormde bloedvaatjes in hypoxisch 
weefsel volledig bestonden uit endotheel cellen afkomstig uit het beenmerg. Dit proces is 
bekend onder de naam vasculogenese. EPO toediening leidt tot mobilisatie van endotheel 
voorloper cellen uit het beenmerg, zoals in hoofdstuk zeven is aangetoond. Daarom zouden 
de effecten van EPO op neovascularisatie gerelateerd kunnen zijn aan de mobilisatie van 
endotheel voorlopercellen uit het beenmerg. Aan de andere kant is het aangetoond dat EPO 
de proliferatie van endotheel cellen stimuleert. Om het effect van EPO op vasculogenese te 
kunnen onderscheiden van angiogenese zijn transgene studies noodzakelijk. Hierin worden 
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dubbel te kleuren voor markers van endotheel cellen én het reporter-eiwit kunnen endotheel 
cellen afkomstig uit het beenmerg worden gedetecteerd. Deze studies zullen meer inzicht 
geven in de effecten van EPO op neovascularisatie.
Over de pleiotrope effecten van EPO in humane studies is weinig bekend. De effecten van 
EPO op reductie van infarct grootte werden bestudeerd in patiënten met een herseninfarct. 
Ehrenreich en collega’s lieten in een dubbel blind gerandomiseerde studie zien dat EPO toe-
diening na een herseninfarct leidde tot een verbeterd functioneren en een trend tot een klei-
ner infarct. Recent hebben we in een kleine veiligheidsstudie de effecten van EPO bestudeerd 
in patiënten met een acuut hartinfarct. Tweeëntwintig patiënten werden gerandomiseerd 
naar EPO (darbepoetin 300 μg) of placebo. Er werden geen ‘adverse events’ gezien tijdens 
de 30 dagen follow-up. De EPO behandelde patiënten lieten een non-significante stijging 
zien in hemoglobine waarden. Daarnaast werd er een significante stijging van het aantal 
endotheel voorloper cellen gezien. Grotere klinische studies zijn nodig om deze pleiotrope 
effecten van EPO te onderzoeken. Met behulp van een Positron Emission Tomography (PET) 
scan zouden de effecten van EPO op het cardiale metabolisme en myocardiale bloedstroom 
kunnen worden onderzocht en de relatie met endotheel voorloper cellen.
Andere interessante ontwikkelingen op het gebied van pleiotrope effecten van EPO worden 
gezien op het vlak van EPO-analogen zonder hematopoëtische effecten. Een van deze mid-
delen is gecarbamyliseerd EPO (C-EPO). Carbamylisatie verandert de structuur van het EPO 
molecuul, waardoor het geen hematopoëtische effecten meer heeft, maar nog wel weefsel 
protectie geeft. In vivo is in knaagdieren aangetoond dat hoge C-EPO doses gedurende langere 
tijd geen verhoging van het hematocriet gaf. Toch remde C-EPO apoptose, reduceerde het de 
infarctgrootte en leidde uiteindelijk tot een verbeterde hartfunctie. De ontwikkeling van deze 
EPO-analogen kunnen mogelijk een rol spelen in de behandeling van het myocard infarct en 
hartfalen in patiënten met normale hemoglobine waarden. De ontdekking van EPO-analogen 
zonder hematopoëtische eigenschappen en het effect van lage doseringen EPO verplaatst de 
rol van EPO van hematopoëse naar cardiale bescherming.135
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Zoals ieder dankwoord eigenlijk begint: promoveren doe je niet alleen en dat is natuurlijk 
ook zo. Veel personen zijn betrokken geweest bij het totstandkomen van dit proefschrift, 
hiervoor mijn grote dank. Een aantal van hen wil ik graag persoonlijk bedanken.
Ten eerste mijn eerste promotor prof. dr. D.J. van Veldhuisen. Beste Dirk-Jan, vanaf het eerste 
moment, toen ik nog co-assistent was, heb je me enthousiast gemaakt voor het onderzoek 
naar erythropoëtine en anemie. Ik wil je bedanken voor de kansen die je me hebt gegeven 
om veel (inter)nationale ervaring op te doen. Ik waardeer je efficiënte manier van werken 
en je praktische instelling om het onderzoek te managen. Verder wil ik je bedanken voor de 
mogelijkheid om mij te kunnen specialiseren tot cardioloog.
Ten tweede wil ik mijn tweede promotor prof. dr. W.H. van Gilst bedanken. Beste Wiek, toen ik 
je de eerste keer ontmoette, moest ik meteen aan jouw colleges over het renine angiotensine 
systeem denken. Dat uiteindelijk zelfs een proefschrift over anemie en erythropoëtine nog 
over ACE zou gaan, had ik toen niet gedacht. Jouw idee om ACE-remmers en hematopoëse te 
linken door Ac-SDKP, resulteerde in een mooie publicatie. Ik waardeer je betrokkenheid bij 
mijn promotie zeer. Jouw scherpe analyses, je humor en laagdrempeligheid maken je tot een 
prettig persoon om mee te werken. Mijn dank hiervoor. 
Verder wil ik mijn beide copromotores Dr. A.A. Voors en Dr. R.G. Schoemaker bedanken. Beste 
Adriaan, ons eerste contact hadden we toen jij nog assistent in Nieuwegein was en het dui-
delijk werd dat je naar Groningen zou komen. De afgelopen 3 jaar ben je bij het EPO-project 
betrokken geweest, hiervoor mijn dank. Hoewel ik zelf niet zo’n auto-freak ben, moet ik 
toch toegeven dat het rijden van Groningen naar Delft in jouw Jaguar een prima alternatief 
was voor de trein of Renault. Beste Regien, bedankt voor je inzet voor, in het bijzonder, het 
experimentele gedeelte van het onderzoek. Jouw ervaringen met het hartfalen model in Rot-
terdam waren erg nuttig. 
De leden van de beoordelingscommissie, Prof. dr. T.J. Rabelink, Prof. dr. E.G. de Vries en Prof. dr. 
F. Zijlstra, wil ik bedanken voor de bereidheid om mijn proefschrift kritisch te beoordelen.
Daarnaast wil dr. R.H. Henning bedanken. Beste Rob, ondanks dat het EPO onderzoek (tot nu 
toe) weinig gericht is geweest op het cellulaire mechanisme, ben je vanaf het begin betrok-
ken. Ik waardeer je heldere analyses en de levendige discussies. 
Zonder de ondersteuning van velen op de Klinische Farmacologie was dit proefschrift er niet 
gekomen. Hiervoor wil ik Egbert, Alex, Jacko, Kristien, Marry, Cecile, Wessel,  Bianca, Maaike 
en Liza bedanken voor hun hulp. Verder wil ik Azuwerus van Buiten bedanken voor zijn be-
reidheid om soms ’s avonds mee te helpen als de experimenten weer eens uitliepen.
Johan Koster en Gideon du Marchie Servaas wil ik bedanken voor hun inzet om bij nacht en 
ontij echocardiogrammen te maken bij de hartfalen ratten.
Graag wil ik ook Alma en Olga, de twee secretaresses van de cardiologie bedanken voor de 
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hulp die jullie hebben geboden tijdens de promotie, maar ook zeker tijdens de laatste loodjes 
van het proefschrift nu ik in Deventer zit. Mijn dank hiervoor. Daarnaast wil ik Ardy, Alexan-
dra en Ellen, secretaresses bij de Klinische Farmacologie bedanken 
‘Van je collega’s moet je het maar hebben’. Het had stelling 11 kunnen zijn en ik onderschrijf 
hem helemaal. De sfeer onder elkaar maakt het werken prettig. Hiervoor wil ik alle leden en 
ex-leden van de Greenhouse bedanken: Pim, Tom, Folkert, Wim, Daan, de 4x’M’ “AF is a 
benign disease” Michiel, Marcella, Martin, Meint, Vincent, Eduard, Tone, Jessica, Christiane 
en Pieter.
Tevens wil ik de collega’s van de Klinische Farmacologie bedanken: Peter, Maria, Els, An-
nemarieke, Cheng, Ying, Mirjam, Willemijn, Bas, Bernadette en Bart (bier drinken aan de 
bar in een Slowaakse trein is zo gek nog niet). Verder wil ik Jan Veerbeek en Jurjen Zandstra 
bedanken voor hun werk voor het EPO-project.
Als arts-onderzoekers was er altijd een goede samenwerking met de cardio-research. Aller-
eerst wil ik Greetje bedanken voor de hulp bij alle trials en natuurlijk de gezelligheid. De vele 
internationale bijeenkomsten waren altijd een succes. Ook Peter wil ik bedanken voor zijn 
onuitputtelijke geduld met alle handtekening op de CRF’s en de vele meetings met vele single 
malt whiskey’s. Verder wil ik Anja, Zaza, Trynke en Margriet bedanken.
Verder wil ik mijn beide paranimfen bedanken voor hun hulp en steun. Ten eerste Erik Lipsic, 
mijn directe collega op het EPO-project. Beste Erik, vanaf het allereerste moment waren we 
beiden betrokken bij hetzelfde onderzoek. Ik waardeer je relativeringsvermogen en de rust 
die je uitstraalt. Ik ben er trots op dat we echte vrienden zijn geworden en ik ben blij dat je 
mijn paranimf wilt zijn. Er is trouwens niks mis met Deventer.
Ten tweede wil ik Jeroen Koning bedanken. Beste Jeroen, toen onze beide vriendinnen nog 
in Amsterdam woonden, wisten wij al dat er niets boven Groningen ging. Onze gezamenlijke 
interesses in goed eten, wijn en wandelen zijn altijd een goede basis voor vakanties en week-
endjes weg. Ik hoop dat we dit in de toekomst nog vaak met jou en Ada ondernemen.
Tot slot wil ik mijn ouders bedanken. Lieve Heit en Mem, bedankt voor alle onvoorwaarde-
lijke steun die jullie Anna-Rixt en mij door de jaren hebben gegeven. Jullie nuchtere kijk op 
het leven en interesse in ons, al moesten jullie ons opzoeken in Nicaragua, waardeer ik heel 
erg.
Lieve Margreet, hoe zou ik jou hier nu in enkele zinnen kunnen bedanken voor wat je door 
de jaren heen voor mij hebt betekend. Jouw hulp en geduld tijdens alle drukte rondom mijn 
proefschrift waardeer ik zeer. Ik ben ervan overtuigd dat we er nog vaak op uit trekken in 
binnen- en buitenland en een goede tijd tegemoet gaan in Deventer. 139 Bibliography
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